TUSTIN, CA–(Marketwire – July 29, 2010) –  US-based Radient Pharmaceuticals Corporation (NYSE Amex: RPC) announced today Perceptive Imagineering has launched a Spanish language website (www.perceptive-imagineering.com/onko-sure) adapted for the Latin American culture in support of the product commercialization for RPC’s proprietary, USFDA-approved Onko-Sure® in vitro diagnostic (IVD) cancer test. 

As RPC’s distribution partner for Central America, South America, Mexico and the Caribbean, Perceptive Imagineering is responsible for commercialization efforts, including product registration, marketing, sales and support for the licensing and distribution of Onko?Sure in these regions. The newly launched site is a companion to RPC’s corporate websites: Radient-Pharma.com and Onko-Sure, and delivers detailed information on Radient Pharmaceuticals, Onko-Sure and Onko-Sure product sales and distribution in Latin American and surrounding regions. This website also includes a valuable FAQ section with answers to the most commonly asked questions about Onko-Sure, scientific literature regarding the test, basic information about cancer and cancer testing in Latin America, RPC’s CLIA laboratory testing resources and general information on cancer screening, testing and treatment.

According to Douglas MacLallan, Chairman and CEO of Radient Pharmaceuticals, “The launch of this new site supports our commercialization efforts in Latin America and serves as a critical communication tool in this geographical region. The site is an invaluable resource to educate our key Latin American audiences, which include cancer patients, the medical and healthcare community at large, existing and prospective investors, partners and suppliers on the Company and Onko-Sure and Onko-Sure’s merits as a non-invasive, simple blood test for cancer screening and testing.”

Perceptive specializes in assisting US medical companies in bringing their products into Latin America. Perceptive Imagineering, LLC is led Dr. Nancy Alvarez, and, under her leadership, her company is well?suited to lead the licensing, distribution and commercialization efforts for RPC’s Onko?Sure cancer test in this market.

Onko-Sure IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.

About Radient Pharma:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is a US-based pharmaceutical company specializing in the research, development and sales of In Vitro Diagnostic Cancer tests. The Company’s focus is on the discovery, development & commercialization of unique high?value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve outcomes for patients. Our Onko?Sure™ IVD cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. For additional information on RPC and its portfolio of cancer products visit the Company’s corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at [email protected] or 1.206.310.5323.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Click here to see all recent news from this company

PLEASANTON, CA–(Marketwire – July 29, 2010) –  APCO Booth #939 — As leading providers of integrated public safety solutions, Positron Front Line and its parent company Tiburon, Inc. announce a strategic partnership agreement with Intrado Inc., the leading provider of 9-1-1 technology solutions. Positron Front Line has also become Intrado’s preferred computer aided dispatch (CAD) solutions provider and will continue to deliver integrated solutions with Intrado’s call-handling applications.

As part of the agreement, Positron Front Line has committed to interoperability with Intrado’s next-generation 9-1-1 (NG9-1-1) voice and data services, ensuring that their solutions are fully compatible with approved industry standards. Through this new strategic partnership, Positron Front Line and Tiburon will work with Intrado to innovate and deliver seamless integration between Intrado’s NG9-1-1 network and value added services and the Positron Front Line VIPER CAD system, allowing NG9-1-1 capabilities and feature rich multimedia content to be accessible by public safety answering point (PSAP) operators and first responders.

NG9-1-1 represents the transformation of the legacy infrastructure of 9-1-1 based on obsolete technology first developed in the 1960s to Internet Protocol (IP) technology of the 21st century. The interoperability and integration of Positron Front Line’s CAD and Intrado’s NG9-1-1 voice and data services will be achieved using ATIS (Alliance for Telecommunications Industry Solutions) approved Emergency Services Messaging Interface (ESMI) and the Request for Assistance Interface (RFAI) standards. These standards are critical to enabling the transition from today’s legacy telecommunications systems to IP-based NG9-1-1 services in the U.S. 

“We are excited to partner with Intrado, a clear leader in next-generation 9-1-1 emergency communication services and we’re proud to be part of a partnership that will help set the standard for the future of emergency response,” said Ian Archbell, general manager of Positron Front Line. “Positron Front Line’s advanced solutions and our commitment, along with Tiburon, to improving standards and solutions for public safety agencies worldwide will further increase with this partnership.”

Intrado’s NG9-1-1 network efficiently delivers voice, text and rich media as well as hosted applications through fully-secured and redundant networks with the goal of allowing agencies and their first responders to enhance the safety, situational awareness and services they provide to their communities.

“Positron Front Line, Tiburon and Intrado are committed to supporting open standards-based technological advancements and have a shared vision about how best to enable the transformation of public safety from today’s largely legacy environments to NG9-1-1,” said Stephen Meer, chief technology officer and co-founder of Intrado. “We’re looking forward to working with Positron Front Line and Tiburon on this important integration initiative, which we believe serves the best interests of the public safety industry as a whole.”

Positron Front Line’s VIPER CAD product integrates an advanced computer aided dispatch system with flexible features, intuitive user interfaces and dynamic administrative control built on a disaster-tolerant distributed architecture. VIPER CAD enables users to manage a variety of CAD activities including tracking calls, responses and resources, changing a unit’s location and obtaining critical information such as emergency type and location. Positron Front Line’s VIPER CAD seamlessly integrates with Intrado NG9-1-1 voice and data services to provide a comprehensive emergency call-taking and dispatching capability with faster, less-costly deployment. VIPER CAD uses open standards to assure operational compatibility not only upon implementation, but throughout the future of NG9-1-1.

About Positron Front Line
As a recognized leader in advanced 9-1-1 technologies and provider of public safety solutions through hosted and traditional delivery models, Positron Front Line delivers integrated, comprehensive, cost-effective public safety solutions for dispatch, mobile communications and records management, and has more than 220 systems installed globally. A subsidiary of Tiburon, Inc., a public safety and security solution provider who serves some of the largest and most complex agencies in the world, Positron Front Line is one of the country’s leading providers of integrated public safety solutions. The company’s roots are in continuously developing, implementing and supporting automated information solutions for the public safety community since 1983. For more information, visit www.positronfrontline.com or call 877-441-4648.

About Tiburon
Established in 1980, Tiburon is the Industry-leading provider of automated public safety and security solutions to meet the demanding and complex needs of law enforcement, fire and rescue and corrections agencies. Tiburon offers fully integrated solutions including computer aided dispatch, records management, mobile data and communications, field reporting and corrections management solutions. From mission-critical conditions to daily operations, across complex multi-agency and multi-jurisdictional environments, Tiburon’s integrated solutions have set the industry standard for capability, scalability and reliability for 30 years. For more information, visit www.tiburoninc.com or call 800-428-5534.

About Intrado
In business for more than 30 years, Intrado has maintained a focus and passion for saving lives and supporting the needs of public safety. Agencies and telecommunication services providers throughout the world depend on Intrado for emergency communication services and technology. Products and services offered include emergency 9-1-1 voice call delivery, comprehensive data management, advanced call routing, emergency location and integrated call handling technologies. Intrado’s dedicated focus on emergency communications technology allows the company to continue pioneering network innovations that save lives and improve emergency response.

Click here to see all recent news from this company

UTICA, NY–(Marketwire – July 29, 2010) – CONMED Corporation (NASDAQ: CNMD) today announced
financial results for the second quarter of 2010.

Sales for the second quarter ended June 30, 2010 were $181.1 million
compared to $164.6 million in the same quarter of 2009, an increase of 10
percent. GAAP diluted earnings per share were $0.25 compared to $0.05 in
the second quarter of 2009. Non-GAAP diluted earnings per share equaled
$0.32 compared to non-GAAP diluted earnings per share of $0.17 in the 2009
second quarter. As discussed below under “Use of Non-GAAP Financial
Measures,” the Company presents various non-GAAP financial measures in this
release. Investors should consider non-GAAP measures in addition to, and
not as a substitute for, or superior to, financial performance measures
prepared in accordance with GAAP. Please refer to the attached
reconciliation between GAAP and non-GAAP financial measures.

For the six months ended June 30, 2010, sales were $357.5 million compared
to $328.6 million in the first six months of 2009, an increase of 8.8
percent. GAAP diluted earnings per share were $0.50 for year-to-date June
2010 compared to $0.20 in the same period of 2009. Non-GAAP diluted
earnings per share were $0.60 for the 2010 six-month period compared to
$0.36 in 2009.

“The results of the 2010 second quarter improved upon the positive
performance of the first quarter of the year,” commented Mr. Joseph J.
Corasanti, President and Chief Executive Officer. “Single-use product
sales, once again, produced solid year-over-year growth, while capital
product sales experienced significant growth, 18.9 percent in constant
currency, over the second quarter of last year. This overall sales growth,
together with the continued realization of cost efficiencies from ongoing
restructuring initiatives, resulted in substantially improved earnings
compared to a year ago.”

International sales in the second quarter of 2010 were $87.9 million,
representing 48.5% of total sales, and $172.9 million for the six-months
ended June 30, 2010. Favorable currency exchange rates in 2010 led to an
increase in sales of $3.2 million compared to exchange rates in the second
quarter of 2009, and $11.1 million for the six-month period of 2010.

Cash provided from operating activities outpaced net income in the second
quarter of 2010 and amounted to $18.5 million, or 10.2 percent of sales.
The cash was used to repay debt and repurchase the Company’s common stock,
as further explained below.

Outlook

Mr. Corasanti added, “We believe that the results of the second quarter of
2010, as well as what we are hearing from our sales force, indicates that
our customers are returning to historical purchasing trends as compared to
the instability experienced in 2009 due to the global economic crisis.
Consequently, we expect that sales in the third quarter of 2010 will
experience a normal seasonal sequential reduction from the second quarter
2010 and that the sales of the fourth quarter of 2010 should be the
strongest of the year, as we’ve seen historically. For the third quarter
of 2010, we expect sales to approximate $174 – $179 million with non-GAAP
diluted earnings per share of $0.25 – $0.30. For the full year of 2010, we
are reiterating our previously communicated guidance, with sales estimated
to be $715 – $725 million and non-GAAP diluted earnings per share of $1.20
– $1.30.”

The sales and earnings forecasts have been developed using July 2010
currency exchange rates and take into account the currency hedges entered
into by the Company. We estimate that 80% of the currency exposure is
hedged for the third quarter 2010 and 60% hedged for the fourth quarter.

The non-GAAP estimates for the year and the third quarter exclude the
additional non-cash interest expense required by recently issued Financial
Accounting Standards Board (“FASB”) guidance, the loss on repurchase and
retirement of our Convertible Notes and all of the manufacturing and
administrative restructuring costs expected to be incurred in 2010.

Restructuring costs

During the second quarter of 2010, the Company consolidated various
administrative functions in its CONMED Linvatec division and continued the
transfer of additional product lines to its Mexican manufacturing facility.
Expenses associated with these activities, including severance and
relocation costs, amounted to $2.0 million in the second quarter of 2010
and $2.5 million for the six months ended June 30, 2010. These charges are
included in the GAAP earnings per share set forth above and are excluded
from the non-GAAP results. CONMED expects additional restructuring charges
for the remainder of 2010 to approximate $1.5 million; these costs are
excluded from non-GAAP earnings estimates.

Stock and bond repurchase

During the second quarter of 2010, utilizing the Company’s current cash
flow, CONMED repurchased approximately 475,000 shares of its common stock,
amounting to $9.5 million, and also repurchased and retired $3.0 million
face value of its 2.5 percent Convertible Notes at a discount of
approximately 3 percent. The remaining availability under the Board of
Directors’ authorization for stock repurchases currently amounts to $37.3
million, and additional shares under this authority may be repurchased
using the Company’s cash flow.

Convertible note interest expense

As previously disclosed, and in accordance with guidance recently issued by
the FASB, the Company is now required to record non-cash interest expense
related to its convertible notes to bring the effective interest rate to a
level approximating that of a non-convertible note of similar size and
tenor. In the second quarters of 2010 and 2009, CONMED recorded additional
non-cash pre-tax interest charges of $1.1 million and $1.0 million,
respectively. For the first six-months of 2010 and 2009, such charges
amounted to $2.1 million in each period. These charges are included in the
GAAP earnings per share set forth above, and excluded from the non-GAAP
amounts.

Accounts receivable financing — change in accounting

As previously disclosed, recently issued FASB guidance requires that
CONMED’s accounting for its accounts receivable financing facility be
changed as of January 1, 2010. Previously, the sale of accounts receivable
to a bank removed the sold receivables from the Company’s balance sheet.
In 2010 and future years, the new guidance requires that the receivables
remain on CONMED’s balance sheet and that the financing transaction be
recorded as a liability. Usage of the facility amounted to $31.0 million
at June 30, 2010. Accordingly, as of June 30, 2010, compared to the
previous off-balance sheet accounting, accounts receivable is $31.0 million
greater because the full amount of receivables remains on the balance
sheet, and the current portion of long-term debt includes the $31.0 million
usage of the receivable facility. Further, cash provided by operating
activities on the June 30, 2010 statement of cash flows is reduced by $29.0
million as a result of the change in accounting. See the attached
reconciliation of cash flow provided by operating activities. This
accounting change had no effect on the consolidated statement of income.

Use of Non-GAAP Financial Measures

Management has disclosed financial measurements in this press announcement
that present financial information that is not in accordance with Generally
Accepted Accounting Principles (“GAAP”). These measurements are not a
substitute for GAAP measurements, although Company management uses these
measurements as aids in monitoring the Company’s on-going financial
performance from quarter-to-quarter and year-to-year on a regular basis,
and for benchmarking against other medical technology companies. Non-GAAP
net income and non-GAAP earnings per share measure the income of the
Company excluding unusual credits or charges that are considered by
management to be outside of the normal on-going operations of the Company.
Management uses and presents non-GAAP net income and non-GAAP earnings per
share because management believes that in order to properly understand the
Company’s short and long-term financial trends, the impact of unusual items
should be eliminated from on-going operating activities. These adjustments
for unusual items are derived from facts and circumstances that vary in
frequency and impact on the Company’s results of operations. Management
uses non-GAAP net income and non-GAAP earnings per share to forecast and
evaluate the operational performance of the Company as well as to compare
results of current periods to prior periods on a consistent basis.
Non-GAAP financial measures used by the Company may be calculated
differently from, and therefore may not be comparable to, similarly titled
measures used by other companies. Investors should consider non-GAAP
measures in addition to, and not as a substitute for, or superior to,
financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its second quarter 2010 conference call live over
the Internet at 10:00 a.m. Eastern Time on Thursday, July 29, 2010. This
webcast can be accessed from CONMED’s web site at www.conmed.com. Replays
of the call will be made available through August 6, 2010.

CONMED Profile

CONMED is a medical technology company with an emphasis on surgical devices
and equipment for minimally invasive procedures and patient monitoring.
The Company’s products serve the clinical areas of arthroscopy, powered
surgical instruments, electrosurgery, cardiac monitoring disposables,
endosurgery and endoscopic technologies. They are used by surgeons and
physicians in a variety of specialties including orthopedics, general
surgery, gynecology, neurosurgery and gastroenterology. Headquartered in
Utica, New York, the Company’s 3,300 employees distribute its products
worldwide from several manufacturing locations.

Forward-Looking Information

This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995 and relate to the
Company’s performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which
could cause actual results, performance or trends, to differ materially
from those expressed in the forward-looking statements herein or in
previous disclosures. The Company believes that all forward-looking
statements made by it have a reasonable basis, but there can be no
assurance that management’s expectations, beliefs or projections as
expressed in the forward-looking statements will actually occur or prove to
be correct. In addition to general industry and economic conditions,
factors that could cause actual results to differ materially from those
discussed in the forward-looking statements in this press release include,
but are not limited to: (i) the failure of any one or more of the
assumptions stated above, to prove to be correct; (ii) the risks relating
to forward-looking statements discussed in the Company’s Annual Report on
Form 10-K for the fiscal year ended December 31, 2009; (iii) cyclical
purchasing patterns from customers, end-users and dealers; (iv) timely
release of new products, and acceptance of such new products by the market;
(v) the introduction of new products by competitors and other competitive
responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and/or (vii) the Company’s ability to devise and execute
strategies to respond to market conditions.

                                 CONMED CORPORATION
                            Second Quarter Sales Summary

                                  Three Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010       Growth         Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        46.0 $        54.4         18.3%         15.4%
   Capital                   15.6          20.5         31.4%         28.8%
                    ------------- ------------- ------------  ------------
                             61.6          74.9         21.6%         18.8%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                19.1          19.1          0.0%         -2.6%
   Capital                   14.4          16.6         15.3%         13.2%
                    ------------- ------------- ------------  ------------
                             33.5          35.7          6.6%          4.2%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                17.3          18.2          5.2%          4.0%
   Capital                    5.4           5.8          7.4%          5.6%
                    ------------- ------------- ------------  ------------
                             22.7          24.0          5.7%          4.4%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                12.5          11.9         -4.8%         -6.4%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                17.3          17.1         -1.2%         -1.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                17.0          17.5          2.9%          2.4%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               129.2         138.2          7.0%          5.1%
   Capital                   35.4          42.9         21.2%         18.9%
                    ------------- ------------- ------------  ------------
                    $       164.6 $       181.1         10.0%          8.1%
                    ============= ============= ============  ============




                                  CONMED CORPORATION
                                Six-Month Sales Summary

                                  Six Months Ended June 30,
                    ------------------------------------------------------

                                                                Constant
                                                                Currency
                         2009          2010        Growth        Growth
                    ------------- ------------- ------------  ------------
                           (in millions)
Arthroscopy
   Single-use       $        92.8 $       109.3         17.8%         13.0%
   Capital                   32.6          37.8         16.0%         12.6%
                    ------------- ------------- ------------  ------------
                            125.4         147.1         17.3%         12.9%
                    ------------- ------------- ------------  ------------

Powered Surgical
 Instruments
   Single-use                37.2          39.3          5.6%          0.0%
   Capital                   29.1          31.4          7.9%          4.1%
                    ------------- ------------- ------------  ------------
                             66.3          70.7          6.6%          1.8%
                    ------------- ------------- ------------  ------------

Electrosurgery
   Single-use                34.3          35.3          2.9%          0.9%
   Capital                   10.8          11.8          9.3%          6.5%
                    ------------- ------------- ------------  ------------
                             45.1          47.1          4.4%          2.2%
                    ------------- ------------- ------------  ------------

Endoscopic
 Technologies
   Single-use                24.5          23.7         -3.3%         -5.7%
                    ------------- ------------- ------------  ------------
Endosurgery
   Single-use and
    reposable                31.8          34.2          7.5%          5.7%
                    ------------- ------------- ------------  ------------
Patient Care
   Single-use                35.5          34.7         -2.3%         -3.1%
                    ------------- ------------- ------------  ------------

Total
   Single-use and
    reposable               256.1         276.5          8.0%          4.6%
   Capital                   72.5          81.0         11.7%          8.4%
                    ------------- ------------- ------------  ------------
                    $       328.6 $       357.5          8.8%          5.4%
                    ============= ============= ============  ============ 



                            CONMED CORPORATION
                    CONSOLIDATED STATEMENTS OF INCOME
                  (in thousands except per share amounts)
                                (unaudited)

                         Three months ended         Six months ended
                              June 30,                  June 30,
                       --------------------       --------------------
                         2009         2010          2009         2010
                       --------     --------      --------     --------

Net sales              $164,569     $181,086      $328,631     $357,451

Cost of sales            83,559       86,411       168,343      170,414
Cost of sales, other
 - Note A                 3,698          992         6,624        1,559
                       --------     --------      --------     --------

Gross profit             77,312       93,683       153,664      185,478
                       --------     --------      --------     --------

Selling and
 administrative          64,147       71,494       126,000      142,046
Research and
 development              7,396        6,441        15,885       14,123
Other expense (income)
 - Note B                   734          970          (602)         970
                       --------     --------      --------     --------
                         72,277       78,905       141,283      157,139
                       --------     --------      --------     -------- 

Income from
 operations               5,035       14,778        12,381       28,339

Gain (loss) on early
 extinguishment of debt       -          (79)        1,083         (79)

Amortization of debt
 discount                 1,013        1,056         2,058        2,108

Interest expense          1,767        1,771         3,255        3,520
                       --------     --------      --------     --------

Income before income
 taxes                    2,255       11,872         8,151       22,632

Provision for income
 taxes                      846        4,566         2,257        8,007
                       --------     --------      --------     --------

Net income             $  1,409     $  7,306      $  5,894     $ 14,625
                       ========     ========      ========     ========

Per share data:

  Net Income
    Basic              $    .05     $    .25      $    .20    $    .50
    Diluted                 .05          .25           .20         .50

  Weighted average
   common shares
    Basic                29,056       29,100        29,043      29,125
    Diluted              29,082       29,295        29,071      29,342

Note A — Included in cost of sales, other in the three and six months
ended June 30, 2009 are $3.7 million and $6.6 million, respectively, in
costs related to the startup of a new manufacturing facility in Chihuahua,
Mexico and the consolidation of two of the Company’s three Utica, New York
area manufacturing facilities. Included in cost of sales, other in the
three and six months ended June 30, 2010 are $1.0 million and $1.6 million,
respectively, related to the moving of additional product lines to the
manufacturing facility in Chihuahua, Mexico.

Note B — Included in other expense (income) in the three months ended June
30, 2009 is $0.7 million related to the consolidation of the Company’s
distribution activities. Included in other expense (income) in the six
months ended June 30, 2009 is a non-cash net pre-tax pension gain of $1.9
million and $1.3 million in costs related to the consolidation of the
Company’s distribution activities. Included in other expense (income) in
the three and six months ended June 30, 2010 is $1.0 million related to the
consolidation of various administrative functions in our orthopedic
division.

                            CONMED CORPORATION
                    CONSOLIDATED CONDENSED BALANCE SHEETS
                               (in thousands)
                                (unaudited)
                                   ASSETS

                                        December 31,    June 30,
                                            2009          2010
                                         ----------    ----------
Current assets:
  Cash and cash equivalents              $   10,098    $    8,490
  Accounts receivable, net                  126,162       142,801
  Inventories                               164,275       170,816
  Deferred income taxes                      14,782        13,764
  Other current assets                       10,293        13,125
                                         ----------    ----------
    Total current assets                    325,610       348,996

Property, plant and equipment, net          143,502       142,070
Deferred income taxes                         1,953         2,002
Goodwill                                    290,505       295,111
Other intangible assets, net                190,849       192,971
Other assets                                  5,994         5,595
                                         ----------    ----------
    Total assets                         $  958,413    $  986,745
                                         ==========    ==========

                     LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
  Current portion of long-term debt       $   2,174    $   33,208
  Other current liabilities                  76,933        73,524
                                         ----------    ----------
    Total current liabilities                79,107       106,732

Long-term debt                              182,195       170,366
Deferred income taxes                        97,916       107,091
Other long-term liabilities                  22,680        24,164
                                         ----------    ----------
    Total liabilities                       381,898       408,353
                                         ----------    ----------

Shareholders' equity:
  Capital accounts                          263,550       256,911
  Retained earnings                         325,370       339,362
  Accumulated other comprehensive
   income (loss)                            (12,405)      (17,881)
                                         ----------    ----------
    Total shareholders' equity              576,515       578,392
                                         ----------    ----------

    Total liabilities and shareholders'
     equity                              $  958,413    $  986,745
                                         ==========    ==========





                             CONMED CORPORATION
               CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
                               (in thousands)
                                (unaudited)

                                                      Six months ended
                                                          June 30,
                                                  ------------------------
                                                      2009         2010
                                                  -----------  -----------
Cash flows from operating activities:
Net income                                        $     5,894  $    14,625
Adjustments to reconcile net income
 to net cash provided by operating
 activities:
  Depreciation and amortization                        19,439       20,581
  Stock-based compensation expense                      2,090        2,082
  Deferred income taxes                                 3,129        7,239
  (Gain) loss on early extinguishment of debt          (1,083)          79
  Sale of accounts receivable to
   (collections for) purchaser                         (3,000)     (29,000)
  Increase (decrease) in cash flows from
   changes in assets and liabilities:
    Accounts receivable                                 7,999        8,718
    Inventories                                        (4,319)     (16,167)
    Accounts payable                                   (7,774)       6,100
    Income taxes payable                               (1,901)        (125)
    Accrued compensation and benefits                  (2,996)          90
    Other assets                                         (830)      (2,884)
    Other liabilities                                  (2,661)      (5,815)
                                                  -----------  -----------
Net cash provided by operating activities              13,987        5,523
                                                  -----------  -----------

Cash flows from investing activities:
  Purchases of property, plant, and
   equipment                                          (12,032)      (7,163)
  Payments related to business acquisitions              (188)      (5,157)
                                                  -----------  -----------
Net cash used in investing activities                 (12,220)     (12,320)
                                                  -----------  -----------

Cash flows from financing activities:
  Payments on debt                                     (9,519)     (14,012)
  Proceeds of debt                                      9,000            -
  Proceeds from secured borrowings, net                     -       31,000
  Repurchase of treasury stock                              -       (9,471)
  Other, net                                           (1,341)      (1,279)
                                                  -----------  -----------
Net cash provided by (used in) financing
 activities                                            (1,860)       6,238
                                                  -----------  -----------

Effect of exchange rate change on cash and cash
 equivalents                                           (1,039)      (1,049)
                                                  -----------  -----------

Net decrease in cash and cash equivalents              (1,132)      (1,608)

Cash and cash equivalents at beginning of period       11,811       10,098
                                                  -----------  -----------

Cash and cash equivalents at end of period        $    10,679  $     8,490
                                                  ===========  ===========





                           CONMED CORPORATION
        RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
          BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
               Three Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------
Reported net income                                     $  1,409  $  7,306
                                                        --------  --------
New plant / facility consolidation costs included
 in cost of sales                                          3,698       992
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Facility consolidation costs included in other expense
 (income)                                                    734         -
                                                        --------  --------

  Total other expense (income)                               734       970
                                                        --------  --------

Loss on early extinguishment of debt                           -        79
                                                        --------  --------

Amortization of debt discount                              1,013     1,056
                                                        --------  --------

Unusual expense (income) before income taxes               5,445     3,097

Provision (benefit) for income taxes on unusual
 expenses                                                 (1,970)   (1,125)
                                                        --------  --------

Net income before unusual items                         $  4,884  $  9,278
                                                        ========  ========

Per share data:

Reported net income
  Basic                                                 $   0.05  $   0.25
  Diluted                                                   0.05      0.25

Net income before unusual items
  Basic                                                 $   0.17  $   0.32
  Diluted                                                   0.17      0.32

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME
         BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT
                Six Months Ended June 30, 2009 and 2010
                (In thousands except per share amounts)
                             (unaudited)

                                                          2009      2010
                                                        --------  --------

Reported net income                                     $  5,894  $ 14,625
                                                        --------  --------

New plant / facility consolidation costs included
 in cost of sales                                          6,624     1,559
                                                        --------  --------

CONMED Linvatec division administrative consolidation          -       970

Pension gain, net                                         (1,882)        -

Facility consolidation costs included in other
 expense (income)                                          1,280         -
                                                        --------  --------

      Total other expense (income)                          (602)      970
                                                        --------  --------

(Gain) loss on early extinguishment of debt               (1,083)       79
                                                        --------  --------

Amortization of debt discount                              2,058     2,108
                                                        --------  --------

Unusual expense (income) before income taxes               6,997     4,716

Provision (benefit) for income taxes on unusual
 expenses                                                 (2,538)   (1,718)
                                                        --------  --------

Net income before unusual items                         $ 10,353  $ 17,623
                                                        ========  ========

Per share data:

Reported net income
      Basic                                             $   0.20  $   0.50
      Diluted                                               0.20      0.50

Net income before unusual items
      Basic                                             $   0.36  $   0.61
      Diluted                                               0.36      0.60

Management has provided the above reconciliation of net income before
unusual items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance as
discussed in the section “Use of Non-GAAP Financial Measures” above. We
have included the amortization of debt discount in our analysis in order to
facilitate comparison with the non-GAAP earnings guidance provided in the
“Outlook” section of this and previous releases which exclude such expense.

                         CONMED CORPORATION
      IMPACT TO STATEMENT OF CASH FLOWS RELATED TO ACCOUNTING
                   CHANGE APPLIED PROSPECTIVELY
              Six Months Ended June 30, 2009 and 2010
                          (In thousands)
                            (unaudited)

                                                          2009     2010
                                                        --------  --------

Reported cash flows from operating activities           $ 13,987  $  5,523
                                                        --------  --------

Sale of accounts receivable accounting change                  -    29,000
                                                        --------  --------

Adjusted cash flows from operating activities           $ 13,987  $ 34,523
                                                        ========  ========


Reported cash flows provided by (used in) financing
 activities                                             $ (1,860) $  6,238
                                                        --------  --------

Proceeds from secured borrowings, net                          -   (31,000)
                                                        --------  --------

Adjusted cash flows provided by (used in) financing
 activities                                             $ (1,860) $(24,762)
                                                        ========  ========

Management has provided the above reconciliation of cash flow from
operations and cash flow from financing activities before the accounting
change as an additional measure that investors can use to compare operating
and financing cash flows between reporting periods. Management believes
these reconciliations provide a useful presentation of cash flows as
discussed in the section “Use of Non-GAAP Financial Measures” above.

MERIDIAN, ID–(Marketwire – July 29, 2010) –  MWI Veterinary Supply, Inc. (NASDAQ: MWIV) (the “Company”) announced financial results today for its third quarter ended June 30, 2010.

Highlights:

• Total revenues were $347.7 million for the quarter, 40% higher than revenues for the same period in the prior fiscal year. Of the 40% increase in total revenues, 17% was due to organic growth in the United States and 23% was related to our acquisition of Centaur Services Limited (“Centaur”). On February 8, 2010, we acquired Centaur, a supplier of animal health products to veterinarians in the United Kingdom. 
• Selling, general and administrative (“SG&A”) expenses as a percentage of total revenues were 7.9% for the quarter, compared to 9.2% for the same period in the prior fiscal year. 
• Operating income increased 38% to $15.1 million, compared to the same period in the prior fiscal year. 
• Net income increased 38% to $9.1 million, compared to the same period in the prior fiscal year. Diluted earnings per share were $0.74 compared to $0.54 in the same period of the prior fiscal year, an increase of 37%. 
• Internet sales to independent veterinary practices and producers in the United States grew by approximately 44% for the quarter compared to the same period in the prior fiscal year. Our product sales from the internet as a percentage of sales in the United States increased to 36% for the quarter as compared to 32% for the same period in the prior fiscal year.
• We generated $5.4 million in cash from operations during the quarter, and as of June 30, 2010 we had borrowings under our credit facilities of $15.9 million. 

“Our results for the quarter continue to demonstrate our strong commitment to providing excellent service and value to our customers and vendor partners,” said Jim Cleary, President and Chief Executive Officer. “Our revenue growth, expense control, earnings growth and value-added services all exceeded our expectations and I would like to thank our employees, customers and vendors for their loyalty to MWI. Also, we continue to be pleased with our integration and collaboration with the Centaur team.”

Quarter ended June 30, 2010 compared to quarter ended June 30, 2009

Total revenues increased 40% to $347.7 million for the quarter ended June 30, 2010, compared to $247.5 million for the quarter ended June 30, 2009. Of the 40% revenue growth, 23% or $57.7 million was related to the acquisition of Centaur. Excluding this acquisition, our revenues attributable to existing customers represented 43% of the growth of total revenues during the quarter ended June 30, 2010. Commissions increased 19% to $4.3 million during the quarter ended June 30, 2010, compared to $3.6 million during the quarter ended June 30, 2009. 

Gross profit increased 27% to $43.9 million for the quarter ended June 30, 2010, compared to $34.5 million for the quarter ended June 30, 2009. Gross profit was benefited by our revenue growth and the addition of Centaur. Gross profit as a percentage of total revenues was 12.6% for the quarter ended June 30, 2010, compared to 13.9% for the quarter ended June 30, 2009. Gross profit as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s gross profit as a percentage of total revenues is generally lower than MWI’s, which serves to reduce the overall gross margin of the consolidated Company when compared to our results for the same period in the prior year. Vendor rebates for the quarter ended June 30, 2010 increased by approximately $540,000 compared to the quarter ended June 30, 2009.

Operating income increased 38% to $15.1 million for the quarter ended June 30, 2010, compared to $10.9 million for the quarter ended June 30, 2009. SG&A expenses increased 21% to $27.4 million for the quarter ended June 30, 2010, compared to $22.7 million for the quarter ended June 30, 2009. SG&A expenses increased primarily due to the acquisition of Centaur and our revenue growth. SG&A expenses as a percentage of total revenues improved to 7.9% for the quarter ended June 30, 2010, compared to 9.2% for the quarter ended June 30, 2009. SG&A expenses as a percentage of total revenues decreased due to the addition of Centaur because Centaur’s SG&A expenses as a percentage of total revenues are generally lower than MWI’s, which serves to reduce the overall SG&A expenses as a percentage of total revenues when compared to our results for the same period in the prior year. Additionally, we had an improvement in our allowance for doubtful accounts as a result of payments made by certain customers. 

Net income increased 38% to $9.1 million for the quarter ended June 30, 2010, compared to $6.6 million for the quarter ended June 30, 2009. Diluted earnings per share were $0.74 and $0.54 for the quarters ended June 30, 2010 and 2009, respectively, an increase of 37%. 

Nine months ended June 30, 2010 compared to nine months ended June 30, 2009

Total revenues increased 25% to $870.4 million for the nine months ended June 30, 2010, compared to $693.8 million for the nine months ended June 30, 2009. Of the 25% revenue growth, 13% or $91.3 million was related to the acquisition of Centaur. Commissions increased 18% to $12.1 million during the nine months ended June 30, 2010, compared to $10.3 million during the nine months ended June 30, 2009.

Gross profit increased by 20% to $119.5 million for the nine months ended June 30, 2010, compared to $99.8 million for the nine months ended June 30, 2009. Gross profit as a percentage of total revenues was 13.7% for the nine months ended June 30, 2010, compared to 14.4% for the nine months ended June 30, 2009. Vendor rebates for the nine months ended June 30, 2010 increased by approximately $165,000 compared to the nine months ended June 30, 2009. 

Operating income increased 36% to $40.5 million for the nine months ended June 30, 2010, compared to $29.8 million for the nine months ended June 30, 2009. SG&A expenses increased 12% to $75.4 million for the nine months ended June 30, 2010, compared to $67.4 million for the nine months ended June 30, 2009. SG&A expenses as a percentage of total revenues were 8.7% for the nine months ended June 30, 2010, compared to 9.7% for the nine months ended June 30, 2009. Included in the increase in SG&A expenses for the nine months ended June 30, 2010 are direct acquisition-related expenses of $1.1 million incurred in connection with the acquisition of Centaur. 

Net income increased 34% to $24.6 million for the nine months ended June 30, 2010, compared to $18.4 million for the nine months ended June 30, 2009. Diluted earnings per share were $1.99 and $1.49 for the nine months ended June 30, 2010 and 2009, respectively, an increase of 34%.

Our cash balance as of June 30, 2010 was $908,000 and we had $15.9 million outstanding on our credit facilities. Compared to September 30, 2009, receivables increased 30%, inventories increased 22% and accounts payable increased 26%. These increases were primarily due to the balances acquired through the acquisition of Centaur as well as our revenue growth.

Business Outlook

The Company updates its previous estimates for the fiscal year ending September 30, 2010. The Company increases its estimate that revenues will be from $1.195 billion to $1.205 billion, which represents growth of 27% to 28% compared to revenues in fiscal year 2009. The Company increases its estimate that diluted earnings per share will be from $2.58 to $2.60 per share, which represents growth of 28% to 29% compared to diluted earnings per share in fiscal year 2009. All of these estimates give effect to the acquisition of Centaur from February 8, 2010 through September 30, 2010. The Company’s previous guidance for the fiscal year ending September 30, 2010 was revenues of approximately $1.16 billion to $1.18 billion and diluted earnings per share of $2.40 to $2.45.

Conference Call

The Company will be hosting a conference call on July 29, 2010 at 11:00 a.m. eastern daylight time to discuss these results and its fiscal year 2010 business outlook in greater detail. Participants can access the conference call by dialing (877) 638-4561 and international callers can access the conference call by dialing (720) 545-0002. The conference call will also be carried live on the Company’s web site at www.mwivet.com. Audio replay will be made available through August 12, 2010 by calling (800) 642-1687 for calls within the United States or (706) 645-9291 for international calls using the passcode 89688546. The conference call will also be available on the Company’s web site, www.mwivet.com.

MWI is a leading distributor of animal health products to veterinarians across the United States of America and United Kingdom. Products MWI sells include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. We market these products to veterinarians in both the companion animal and production animal markets. For more information about MWI, please visit our website at www.mwivet.com. For investor relations information please contact Mary Pat Thompson, Senior Vice President of Finance and Administration, and Chief Financial Officer at (208) 955-8930 or email [email protected].

Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those discussed in filings made by the Company with the Securities and Exchange Commission. Many of the factors that will determine the Company’s future results are beyond the ability of management to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Important assumptions and other important factors that could cause actual results to differ materially from those set forth in the forward-looking information include the impact of vendor consolidation on our business; changes in or availability of vendor rebate programs; vendor rebates based upon attaining certain growth goals; changes in the way vendors introduce products to market; exclusivity requirements with certain vendors that may prohibit us from distributing competing products manufactured by other vendors; risks associated with our international operations; transitional challenges associated with acquisitions, including the failure to achieve anticipated synergies; financial risks associated with acquisitions; the impact of general economic trends on our business; the recall of a significant product by one of our vendors; extended shortage or backorder of a significant product by one of our vendors; seasonality; the timing and effectiveness of marketing programs offered by our vendors; the timing of the introduction of new products and services by our vendors; the ability to borrow on our credit line, extend the terms of our credit line or obtain alternative financing on favorable terms or at all; risks from potential increases in variable interest rates; unforeseen litigation; a disruption caused by adverse weather or other natural conditions; inability to ship products to the customer as a result of technological or shipping disruptions; and competition. Other factors include changes in the rate of inflation; changes in state or federal legislation or regulation; the continued safety of the products the Company sells; and changes in the general economy. Investors should also be aware that while we do, from time to time, communicate with securities analysts, it is against our policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, we have a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of MWI Veterinary Supply, Inc.

HOUSTON, TX–(Marketwire – July 28, 2010) –  A growing demand for hand, wrist and elbow specialist Dr. David Hildreth, who once practiced exclusively at the Texas Medical Center, has prompted the growth of offices in Sugar Land and Katy. The renowned Houston orthopedic surgeon formerly of Baylor College of Medicine and The Methodist Hospital System is working to meet growing demand since joining The Richmond Bone & Joint Clinic.

Dr. Hildreth is not only available to patients in Richmond, but also now in Sugar Land and Katy. The Sugar Land office is located at 15035 SW Freeway, near Williams Trace Blvd., and the Katy office is located at 21222 Kingsland Blvd.

An original founder of the Tennis Elbow Institute of Houston and among the first Eaton-trained Dupuytren’s physicians in Houston, Dr. Hildreth has served as lead investigator in studies changing the treatment options available for many common hand, wrist and elbow conditions.

A published author who served as an associate professor at The Methodist Hospital System and Weill Medical College of Cornell University, Dr. Hildreth stays ahead of “standard of care” to bring his patients such advanced treatment options as Needle Aponeurotomy (NA) and non surgical XIAFLEX® injection therapy in the treatment of Dupuytren’s Contracture, as well as less invasive treatment for carpal and cubital tunnel syndromes, sports injuries and degenerative joint conditions.

“Practicing at a specialized orthopedic clinic such as RBJC, we have the advantage of offering the latest treatment options far more rapidly. We devote a tremendous amount of time studying the new techniques and technology within the industry to remain ahead of current ‘standards,'” said Hildreth.

“These new offices are a response to patients wanting personalized care and easier access to a higher quality of medical services in their neighborhood. We’re pleased to be able to provide them with this increased accessibility,” added Hildreth.

Featured in “Medical Advances” of Newsweek magazine and named for the fifth consecutive year among the Texas Monthly list of Super Doctors and H Texas magazine’s Top Docs, view a video of Dr. Hildreth and his staff as they provide personalized treatment and rehabilitation programs for hand, wrist and elbow patients.

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) – Sun Healthcare Group, Inc. (NASDAQ: SUNH) today
announced its operating results for the second quarter ended June 30, 2010.

Normalized results for the second-quarter period ended June 30, 2010:

--  consolidated revenues rose 1.3 percent to $474.6 million, compared to
    the same period in 2009;
    -- increased patient acuity resulted in an overall improvement in
       reimbursement rates;
    -- hospice and rehabilitation therapy businesses showed solid revenue
       growth;
--  consolidated adjusted EBITDAR was $62.8 million and adjusted EBITDAR
    margin was 13.2 percent;
--  consolidated adjusted EBITDA was $44.0 million and adjusted EBITDA
    margin was 9.3 percent;
--  diluted earnings per share from continuing operations were $0.26;
--  free cash flow was $20.6 million for the quarter;
--  results included $0.9 million of non-recurring project costs associated
    with the continued implementation of a clinical/billing platform; and
--  results have been normalized to exclude a pre-tax charge of $2.2
    million for transaction costs associated with the Separation
    transaction described in further detail later in this press release.

Commenting on the Company’s second-quarter results, Richard K. Matros,
Sun’s chairman and chief executive officer, remarked, “We have navigated
through a particularly tough time in our sector with only a slight
reduction in normalized adjusted EBITDAR and EBITDA. As we get closer to
the Oct. 1 effective date for changes in Medicare reimbursement, which
include the implementation of RUGs IV, restrictions on concurrent therapy
and elimination of the lookback period, we are bullish on the growth
opportunities that these changes provide. We still anticipate top line
softness and no growth in Medicaid rates in 2011, given the continued
budget pressures that exist in many states in which we operate. However, we
expect Medicare growth in both pricing and acuity, a decided improvement
over what we have experienced in 2010 coming off the Medicare rate
reduction in October 2009. The previously announced separation of our
operating assets and our real estate assets and the creation of the REIT
are proceeding as planned.” Matros added, “We are reaffirming our
previously announced 2010 guidance and believe that the high end of the
guidance is achievable.”

Segment Updates

On a year-over-year basis for the quarter, revenue growth in Sun’s
inpatient services business totaled $5.3 million, or 1.3 percent, due
principally to revenue growth in SolAmor, the Company’s hospice business.
SolAmor’s revenues increased from $6.3 million to $11.4 million, due to
census expansion derived from same-store census growth as well as an
October 2009 acquisition. SolAmor contributed $2.2 million of adjusted
EBITDA for the quarter and an adjusted EBITDA margin of 19.6 percent. In
the quarter, revenues from SunBridge’s nursing center operations were flat
on a year-over-year basis due to declines in nursing center customer base
and the lingering effect of the October 2009 Medicare rate reduction,
partially offset by acuity-driven rate growth. This acuity growth was
evidenced by Medicare Rehab RUG utilization of 90.9 percent, which was up
240 basis points year-over-year, and Medicare REX utilization of 45.8
percent, which was up 370 basis points year-over-year. On an overall basis,
the adjusted EBITDAR for inpatient services was $71.6 million for the
quarter, with an adjusted EBITDAR margin of 17.0 percent.

SunDance, Sun’s rehabilitation therapy services business, experienced
revenue growth of $6.5 million, or 14.7 percent, in the quarter as
non-affiliated contracts were increased by nine to a high of 335 contracts
as of June 30, 2010, and revenue per contract also increased by 10 percent.
Given the strong revenue results, adjusted EBITDA margin also expanded in
the quarter by 70 basis points, producing an 8.0 percent adjusted EBITDA
margin.

The slow economy continues to impact the demand for temporary medical
staffing across the industry. Accordingly, revenues from CareerStaff,
Sun’s medical staffing services business, were down compared to revenues in
the second quarter of 2009. Despite the decline in revenues, CareerStaff
achieved adjusted EBITDA margin growth on a sequential quarter basis of 140
basis points to 8.5 percent for the quarter.

Mr. Matros commented, “We have completed the installation of our clinical
billing platform for our nursing centers and are experiencing the benefits
of this integrated system in our daily management of the business. We
opened three new Rehab Recovery Suites® (RRS) during the quarter,
bringing our RRS count to 66 units and our RRS beds to a high of 1,632, a
6.8 percent increase in beds since the beginning of the year, with the
majority of the RRS bed growth coming in the second half of 2010 as
planned. The revenue growth we have achieved in our rehabilitation business
was solid this quarter, driven by the increase in contracts as well as the
increase in revenue per contract. Our hospice business continues to perform
consistently with our expectations, and although our medical staffing
business continues to operate in a tough environment, its adjusted EBITDA
margin remains solid.”

Conference Call

As previously announced, investors and the general public are invited to
listen to a conference call with Sun’s senior management on Thursday, July
29, 2010, at 10 a.m. Pacific / 1 p.m. Eastern, to discuss the Company’s
earnings for the second quarter of 2010.

To listen to the conference call, dial (888) 437-9315 and refer to Sun
Healthcare Group. A recording of the call will be available from 4 p.m.
Eastern on July 29, 2010, until midnight Eastern on Aug. 30, 2010, by
calling (888) 203-1112 and using access code 1833674.

About Sun Healthcare Group, Inc.

Sun Healthcare Group, Inc.’s (NASDAQ: SUNH) subsidiaries provide nursing,
rehabilitative and related specialty healthcare services principally to the
senior population in the United States. Sun’s core business is providing,
through its subsidiaries, inpatient services, primarily through 166 skilled
nursing centers, 16 combined skilled nursing, assisted and independent
living centers, 10 assisted living centers, two independent living centers
and eight mental health centers. On a consolidated basis, Sun has annual
revenues of $1.9 billion and approximately 30,000 employees in 46 states.
At June 30, 2010, SunBridge centers had 23,209 licensed beds located in 25
states, of which 22,427 were available for occupancy. Sun also provides
rehabilitation therapy services to affiliated and non-affiliated centers
through its SunDance subsidiary, medical staffing services through its
CareerStaff Unlimited subsidiary and hospice services through its SolAmor
subsidiary.

In May 2010, Sun announced a plan to restructure its business by separating
its real estate assets and its operating assets into two separate publicly
traded companies (the “Separation”), subject to the approval of
stockholders and other conditions. The Separation will be accomplished by
distributing to stockholders the stock of SHG Services, Inc., a Sun
subsidiary that will own and operate the operating subsidiaries.
Substantially all of Sun’s owned real estate assets will continue to be
owned by Sun, which will, after the Separation, merge into its subsidiary,
Sabra Health Care REIT, Inc. Following this merger, SHG Services, Inc. will
change its name to Sun Healthcare Group, Inc. The common stock of both
companies is expected to trade on the NASDAQ Global Select Market. The
Separation is expected to be completed in the fourth quarter of 2010.

Forward-Looking Statement

Statements made in this release that are not historical facts are
“forward-looking” statements (as defined in the Private Securities
Litigation Reform Act of 1995) that involve risks and uncertainties and are
subject to change at any time. These forward-looking statements may
include, but are not limited to, statements containing words such as
“anticipate,” “believe,” “plan,” “estimate,” “expect,” “hope,” “intend,”
“may” and similar expressions. Forward-looking statements in this release
include all statements regarding our expected future financial position and
results of operations, business strategy, the impact of reductions in
reimbursements and other changes in government reimbursement programs, the
timing and impact of the equity offering and the Separation and
transactions related thereto, growth opportunities and plans and objectives
of management for future operations. Factors that could cause actual
results to differ are identified in the public filings made by the Company
with the Securities and Exchange Commission and include changes in Medicare
and Medicaid reimbursements; the impact that any healthcare reform
legislation will have on our business; our ability to maintain the
occupancy rates and payor mix at our healthcare centers; potential
liability for losses not covered by, or in excess of, our insurance; the
effects of government regulations and investigations; the significant
amount of our indebtedness, covenants in our debt agreements that may
restrict our activities and our ability to make acquisitions, to incur more
indebtedness and to refinance indebtedness on favorable terms; our ability
to accomplish the Separation and the proposed equity and debt financings,
the impact of the current economic downturn on our business; increasing
labor costs and the shortage of qualified healthcare personnel; and our
ability to receive increases in reimbursement rates from government payors
to cover increased costs. More information on factors that could affect our
business and financial results are included in our public filings made with
the Securities and Exchange Commission, including our Annual Report on
Forms 10-K and Quarterly Reports on Form 10-Q, copies of which are
available on Sun’s web site, www.sunh.com. There may be additional risks of
which we are presently unaware or that we currently deem immaterial.

The forward-looking statements involve known and unknown risks,
uncertainties and other factors that are, in some cases, beyond our
control. We caution investors that any forward-looking statements made by
Sun are not guarantees of future performance and are only made as of the
date of this release. We disclaim any obligation to update any such factors
or to announce publicly the results of any revisions to any of the
forward-looking statements to reflect future events or developments.

Adjusted EBITDA, adjusted EBITDAR and free cash flow, as used in this press
release and in the accompanying tables, which are non-GAAP financial
measures, are each reconciled to their respective GAAP recognized financial
measures in the accompanying tables. In addition, the normalizing
adjustments to adjusted EBITDA, adjusted EBITDAR and earnings per share as
discussed in this press release and shown, together with normalizing
adjustments to other financial measures, in the accompanying tables, are
non-GAAP adjustments, and are reconciled to GAAP financial measures in the
accompanying tables.

Additional Information

In connection with the Separation, SHG Services, Inc. has filed with the
SEC a Registration Statement on Form S-1 and Sabra Health Care REIT, Inc.
has filed with the SEC a Registration Statement on Form S-4, each
containing an identical proxy statement/prospectus. The definitive proxy
statement/prospectus will be mailed to Sun stockholders. In addition, Sun
has filed a shelf registration statement on Form S-3 (including a
prospectus) relating to shares of common stock of Sun with the SEC, and
such registration statement has been declared effective. This release does
not constitute an offer to sell or a solicitation of an offer to buy shares
of Sun common stock; nor shall there be any offer, solicitation or sale of
these securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful. The offering of shares of Sun
common stock may be made only by means of a prospectus relating to the
proposed offering.

Before making any voting or investment decision, Sun stockholders and
investors are urged to read the proxy statement/prospectus, the prospectus
in the registration statement on FormS-3, and other documents filed with
the SEC carefully and in their entirety when they become available because
they will contain important information about the proposed transactions.
Stockholders will be able to obtain these documents free of charge at the
SEC’s web site at www.sec.gov. In addition, investors and stockholders of
Sun may obtain free copies of the documents filed with the SEC by
contacting Sun’s investor relations department at (505) 468-2341 (TDD
users, please call (505) 468-4458) or by sending a written request to
Investor Relations, Sun Healthcare Group, Inc. 101 Sun Avenue N.E.,
Albuquerque, N.M. 87109.

Sun and its directors and executive officers and other members of its
management and employees may be deemed to be participants in the
solicitation of proxies from the stockholders of Sun in connection with the
transactions described in this release. Information about the directors
and executive officers of Sun and their ownership of shares of Sun common
stock are set forth in the Annual Report on Form 10-K for the year ended
December 31, 2009, filed with the SEC on March 5, 2010, and in the
definitive proxy statement relating to Sun’s 2010 Annual Meeting of
Stockholders filed with the SEC on April 30, 2010. These documents can be
obtained free of charge from the sources indicated above. Additional
information regarding the interests of these participants will also be
included in the definitive proxy statement/prospectus when it becomes
available.

                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)



                                                    For the      For the
                                                 Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   474,618  $   468,713

Depreciation and amortization                          12,561       11,153

Interest expense, net                                  11,776       12,465

Pre-tax income                                         17,403       18,328

Income tax expense                                      7,135        7,517

Income from continuing operations                      10,268       10,811

Loss from discontinued operations                        (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Diluted earnings per share                        $      0.22  $      0.23
                                                  ===========  ===========


Adjusted EBITDAR                                  $    60,550  $    60,201
Margin - Adjusted EBITDAR                                12.8%        12.8%

Adjusted EBITDAR normalized                       $    62,798  $    64,501
Margin - Adjusted EBITDAR normalized                     13.2%        13.8%


Adjusted EBITDA                                   $    41,740  $    41,986
Margin - Adjusted EBITDA                                  8.8%         9.0%

Adjusted EBITDA normalized                        $    43,988  $    46,286
Margin - Adjusted EBITDA normalized                       9.3%         9.9%


Pre-tax income continuing operations - normalized $    19,651  $    22,628

Income tax expense - normalized                   $     8,057  $     9,280

Income from continuing operations - normalized    $    11,594  $    13,348

Diluted earnings per share - normalized           $      0.26  $      0.30

Net income - normalized                           $    11,299  $    12,981

Diluted earnings per share - normalized           $      0.25  $      0.30

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES                

                       KEY INCOME STATEMENT FIGURES
                               CONSOLIDATED
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------

Revenue                                           $   947,874  $   936,843

Depreciation and amortization                          25,007       21,875

Interest expense, net                                  23,752       25,191

Pre-tax income                                         35,198       37,989

Income tax expense                                     14,431       15,575

Income from continuing operations                      20,767       22,414

Loss from discontinued operations                        (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Diluted earnings per share                        $      0.46  $      0.46
                                                  ===========  ===========


Adjusted EBITDAR                                  $   121,319  $   121,673
Margin - Adjusted EBITDAR                                12.8%        13.0%

Adjusted EBITDAR normalized                       $   123,567  $   125,973
Margin - Adjusted EBITDAR normalized                     13.0%        13.4%


Adjusted EBITDA                                   $    83,957  $    85,095
Margin - Adjusted EBITDA                                  8.9%         9.1%

Adjusted EBITDA normalized                        $    86,205  $    89,395
Margin - Adjusted EBITDA normalized                       9.1%         9.5%


Pre-tax income continuing operations - normalized $    37,446  $    42,289

Income tax expense - normalized                   $    15,353  $    17,338

Income from continuing operations - normalized    $    22,093  $    24,951

Diluted earnings per share - normalized           $      0.50  $      0.57

Net income - normalized                           $    21,497  $    23,224

Diluted earnings per share - normalized           $      0.49  $      0.53

   See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
   "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

   See normalizing adjustments in the table "Normalizing Adjustments -
   Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                        CONSOLIDATED BALANCE SHEETS
                    (in thousands, except share data)



                                                    June 30,   December 31,
                                                      2010        2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)
                          ASSETS

Current assets:
  Cash and cash equivalents                       $   106,974  $   104,483
  Restricted cash                                      24,732       24,034
  Accounts receivable, net                            220,373      220,319
  Prepaid expenses and other assets                    18,021       21,757
  Deferred tax assets                                  69,544       68,415
                                                  -----------  -----------
    Total current assets                              439,644      439,008

Property and equipment, net                           620,999      622,682
Intangible assets, net                                 52,640       53,931
Goodwill                                              338,364      338,296
Restricted cash, non-current                              348        3,317
Deferred tax assets                                    96,180      108,999
Other assets                                            5,000        4,961
                                                  -----------  -----------
    Total assets                                  $ 1,553,175  $ 1,571,194
                                                  ===========  ===========


          LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
  Accounts payable                                $    52,922  $    57,109
  Accrued compensation and benefits                    63,015       58,953
  Accrued self-insurance obligations, current          43,794       45,661
  Income taxes payable                                    338            -
  Other accrued liabilities                            55,507       55,265
  Current portion of long-term debt and capital
   lease obligations                                   74,827       46,416
                                                  -----------  -----------
  Total current liabilities                           290,403      263,404

Accrued self-insurance obligations, net of
 current portion                                      128,657      121,948
Long-term debt and capital lease obligations, net
 of current portion                                   588,736      654,132
Unfavorable lease obligations, net                     11,233       12,663
Other long-term liabilities                            60,692       69,983
                                                  -----------  -----------
  Total liabilities                                 1,079,721    1,122,130


Stockholders' equity:
  Preferred stock of $.01 par value, authorized
   10,000,000 shares, no shares were issued and
   outstanding as of June 30, 2010 and
   December 31, 2009                                        -            -
  Common stock of $.01 par value, authorized
   125,000,000 shares, 43,980,405 and 43,764,240
   shares issued and outstanding as of June 30, 2010
   and December 31, 2009, respectively                    440          438
  Additional paid-in capital                          657,875      655,667
  Accumulated deficit                                (183,841)    (204,012)
  Accumulated other comprehensive loss, net            (1,020)      (3,029)
                                                  -----------  -----------
                                                      473,454      449,064
                                                  -----------  -----------
    Total liabilities and stockholders' equity    $ 1,553,175  $ 1,571,194
                                                  ===========  ===========



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   474,618  $   468,713
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     267,880      261,967
  Self-insurance for workers' compensation and
   general and professional liability insurance        14,558       16,809
  Operating administrative costs                       13,301       13,192
  Other operating costs                                95,884       94,530
  Center rent expense                                  18,810       18,215
  General and administrative expenses                  15,157       15,721
  Depreciation and amortization                        12,561       11,153
  Provision for losses on accounts receivable           5,040        6,293
  Interest, net of interest income of $73 and $96,
   respectively                                        11,776       12,465
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              457,215      450,385
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            17,403       18,328
Income tax expense                                      7,135        7,517
                                                  -----------  -----------
Income from continuing operations                      10,268       10,811
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (295)        (708)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -           (7)
                                                  -----------  -----------
Loss from discontinued operations, net                   (295)        (715)
                                                  -----------  -----------

Net income                                        $     9,973  $    10,096
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                    -        (0.02)
                                                  -----------  -----------
Net income                                        $      0.23  $      0.23
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.23  $      0.25
  Loss from discontinued operations, net                (0.01)       (0.02)
                                                  -----------  -----------
Net income                                        $      0.22  $      0.23
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,233       43,851
  Diluted                                              44,352       43,960



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                      CONSOLIDATED INCOME STATEMENTS
                  (in thousands, except per share data)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Total net revenues                                $   947,874  $   936,843
                                                  -----------  -----------
Costs and expenses:
  Operating salaries and benefits                     534,918      524,878
  Self-insurance for workers' compensation and
   general and professional liability insurance        29,096       31,462
  Operating administrative costs                       25,589       25,769
  Other operating costs                               193,363      190,309
  Center rent expense                                  37,362       36,578
  General and administrative expenses                  30,424       32,471
  Depreciation and amortization                        25,007       21,875
  Provision for losses on accounts receivable          10,917       10,281
  Interest, net of interest income of $163 and
   $203, respectively                                  23,752       25,191
  Transaction costs                                     2,248            -
  Loss on sale of assets, net                               -           40
                                                  -----------  -----------
Total costs and expenses                              912,676      898,854
                                                  -----------  -----------

Income before income taxes and discontinued
 operations                                            35,198       37,989
Income tax expense                                     14,431       15,575
                                                  -----------  -----------
Income from continuing operations                      20,767       22,414
                                                  -----------  -----------

Discontinued operations:
  Loss from discontinued operations, net of
   related taxes                                         (596)      (1,760)
  Loss on disposal of discontinued operations, net
   of related taxes                                         -         (315)
                                                  -----------  -----------
Loss from discontinued operations, net                   (596)      (2,075)
                                                  -----------  -----------

Net income                                        $    20,171  $    20,339
                                                  ===========  ===========


Basic income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net income                                        $      0.46  $      0.46
                                                  ===========  ===========

Diluted income per common and common equivalent
 share:
  Income from continuing operations               $      0.47  $      0.51
  Loss from discontinued operations, net                (0.01)       (0.05)
                                                  -----------  -----------
Net Income                                        $      0.46  $      0.46
                                                  ===========  ===========

Weighted average number of common and
 common equivalent shares outstanding:
  Basic                                                44,119       43,748
  Diluted                                              44,234       43,891



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                 Three Months  Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $     9,973  $    10,096
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      12,561       11,153
    Amortization of favorable and unfavorable
     lease intangibles                                   (474)        (474)
    Provision for losses on accounts receivable         5,125        6,294
    Loss on sale of assets, including
     discontinued operations, net                           -           53
    Stock-based compensation expense                    1,694        1,641
    Deferred taxes                                      6,755        6,345
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                                (4,871)     (11,599)
    Restricted cash                                     3,427        1,415
    Prepaid expenses and other assets                  (1,670)        (392)
    Accounts payable                                    7,140       (1,527)
    Accrued compensation and benefits                  (4,362)      (3,907)
    Accrued self-insurance obligations                  2,805          344
    Income taxes payable                                 (290)           -
    Other accrued liabilities                          (2,457)      (5,571)
    Other long-term liabilities                        (4,144)         885
                                                  -----------  -----------
     Net cash provided by operating activities         31,212       14,756
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (10,656)     (13,137)
 Purchase of leased real estate                             -       (3,275)
                                                  -----------  -----------
    Net cash used for investing activities            (10,656)     (16,412)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (16,036)      (2,075)
 Distribution to non-controlling interest                   -         (549)
 Proceeds from issuance of common stock                     -            7
                                                  -----------  -----------
    Net cash used for financing activities            (16,036)      (2,617)
                                                  -----------  -----------

Net (decrease) increase in cash and cash
 equivalents                                            4,520       (4,273)
Cash and cash equivalents at beginning of period      102,454       99,945
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:

   Net cash provided by operating activities      $    31,212  $    14,756
   Capital expenditures                               (10,656)     (13,137)
                                                  -----------  -----------
    Free cash flow                                $    20,556  $     1,619
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



               SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

                  CONSOLIDATED STATEMENTS OF CASH FLOWS
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  -----------  -----------
                                                  (unaudited)  (unaudited)

Cash flows from operating activities:
 Net income                                       $    20,171  $    20,339
 Adjustments to reconcile net income to net cash
  provided by operating activities, including
  discontinued operations:
    Depreciation and amortization                      25,007       21,875
    Amortization of favorable and unfavorable
     lease intangibles                                   (948)        (876)
    Provision for losses on accounts receivable        11,139       10,281
    Loss on sale of assets, including
     discontinued operations, net                           -          575
    Stock-based compensation expense                    3,087        2,909
    Deferred taxes                                     11,691       12,520
 Changes in operating assets and liabilities, net
  of acquisitions:
    Accounts receivable                               (11,193)     (21,667)
    Restricted cash                                     2,271        9,521
    Prepaid expenses and other assets                   2,613         (238)
    Accounts payable                                    1,281       (5,063)
    Accrued compensation and benefits                   4,062          366
    Accrued self-insurance obligations                  4,842        1,251
    Income taxes payable                                  338            -
    Other accrued liabilities                              13         (825)
    Other long-term liabilities                        (5,099)       1,181
                                                  -----------  -----------
     Net cash provided by operating activities         69,275       52,149
                                                  -----------  -----------

Cash flows from investing activities:
 Capital expenditures                                 (27,714)     (25,002)
 Purchase of leased real estate                             -       (3,275)
 Proceeds from sale of assets held for sale                 -        2,174
                                                  -----------  -----------
    Net cash used for investing activities            (27,714)     (26,103)
                                                  -----------  -----------

Cash flows from financing activities:
 Principal repayments of long-term debt and
  capital lease obligations                           (36,976)     (21,687)
 Payment to non-controlling interest                   (2,025)           -
 Distribution to non-controlling interest                 (69)        (860)
 Proceeds from issuance of common stock                     -           20
                                                  -----------  -----------
    Net cash used for financing activities            (39,070)     (22,527)
                                                  -----------  -----------

Net increase in cash and cash equivalents               2,491        3,519
Cash and cash equivalents at beginning of period      104,483       92,153
                                                  -----------  -----------
Cash and cash equivalents at end of period        $   106,974  $    95,672
                                                  ===========  ===========

Reconciliation of net cash provided by operating
 activities to free cash flow:
   Net cash provided by operating activities      $    69,275  $    52,149
   Capital expenditures                               (27,714)     (25,002)
                                                  -----------  -----------
    Free cash flow                                $    41,561  $    27,147
                                                  ===========  ===========

Free cash flow is defined as net cash flow provided by operating activities
less cash used for capital expenditures.  Free cash flow is used by
management to evaluate discretionary cash flow potentially available for
debt service and other financing activities.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            RECONCILIATION OF NET INCOME TO EBITDA and EBITDAR
                              (in thousands)



                                                    For the      For the
                                                  Three Months Three Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

Total net revenues                                $    474,618 $    468,713
                                                  ------------ ------------

Net income                                        $      9,973 $     10,096
                                                  ------------ ------------


  Income from continuing operations                     10,268       10,811

  Income tax expense                                     7,135        7,517

  Interest, net                                         11,776       12,465

  Depreciation and amortization                         12,561       11,153
                                                  ------------ ------------

EBITDA                                            $     41,740 $     41,946

  Loss on sale of assets, net                                -           40

Adjusted EBITDA                                   $     41,740 $     41,986


  Center rent expense                                   18,810       18,215
                                                  ------------ ------------

Adjusted EBITDAR                                  $     60,550 $     60,201
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization. Adjusted EBITDA
is defined as EBITDA before loss on sale of assets, net. Adjusted EBITDAR
is defined as Adjusted EBITDA before center rent expense. Adjusted EBITDA
and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole. Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles. As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity. Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations. Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

   RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA and ADJUSTED EBITDAR
                              (in thousands)


                                                    For the      For the
                                                  Six Months   Six Months
                                                     Ended        Ended
                                                    June 30,     June 30,
                                                      2010         2009
                                                  ------------ ------------
                                                  (unaudited)  (unaudited)

 Total net revenues                               $    947,874 $    936,843
                                                  ------------ ------------

 Net income                                       $     20,171 $     20,339
                                                  ------------ ------------


  Income from continuing operations                     20,767       22,414

  Income tax expense                                    14,431       15,575

  Interest, net                                         23,752       25,191

  Depreciation and amortization                         25,007       21,875
                                                  ------------ ------------

 EBITDA                                           $     83,957 $     85,055

  Loss on sale of assets, net                                -           40
                                                  ------------ ------------

 Adjusted EBITDA                                  $     83,957 $     85,095


  Center rent expense                                   37,362       36,578
                                                  ------------ ------------

 Adjusted EBITDAR                                 $    121,319 $    121,673
                                                  ============ ============

EBITDA is defined as earnings before loss on discontinued operations,
income taxes, interest, net, depreciation and amortization.  Adjusted
EBITDA is defined as EBITDA before loss on sale of assets , net.  Adjusted
EBITDAR is defined as Adjusted EBITDA before center rent expense.  Adjusted
EBITDA and Adjusted EBITDAR are used by management to evaluate financial
performance and resource allocation for each entity within the operating
units and for the Company as a whole.  Adjusted EBITDA and Adjusted EBITDAR
are commonly used as analytical indicators within the healthcare industry
and also serve as measures of leverage capacity and debt service ability.
Adjusted EBITDA and Adjusted EBITDAR should not considered as measures of
financial performance under generally accepted accounting principles.  As
the items excluded from Adjusted EBITDA and Adjusted EBITDAR are
significant components in understanding and assessing finance performance,
Adjusted EBITDA and Adjusted EBITDAR should not be considered in isolation
or as alternatives to net income, cash flows generated by or used in
operating, investing or financing activities or other financial statement
data presented in the consolidated financial statements as indicators of
financial performance or liquidity.  Because Adjusted EBITDA and Adjusted
EBTIDAR are not measurements determined in accordance with U.S. generally
accepted accounting principles and are thus susceptible to varying
calculations.  Adjusted EBITDA and Adjusted EBITDAR as presented may not be
comparable to other similarly titled measures of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2010
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $421,720  $30,017  $22,875  $      6  $      -  $474,618
Affiliated revenue       -   21,034      496         -   (21,530)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $421,720  $51,051  $23,371  $      6  $(21,530) $474,618
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 39,014  $ 3,921  $ 1,802  $(34,469) $      -  $ 10,268
Income tax expense       -        -        -     7,135         -     7,135
Interest, net        2,706        -        -     9,070         -    11,776
Depreciation and
 amortization       11,418      159      182       802         -    12,561
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Loss on sale of
 assets, net             -        -        -         -         -         -
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 53,138  $ 4,080  $ 1,984  $(17,462) $      -  $ 41,740

Center rent
 expense            18,489      118      203         -         -    18,810
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(17,462) $      -  $ 60,550
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 53,138  $ 4,080  $ 1,984  $(15,214) $      -  $ 43,988
  Normalized
   Adjusted
   EBITDAR        $ 71,627  $ 4,198  $ 2,187  $(15,214) $      -  $ 62,798


   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          8.8%
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    12.6%     8.0%     8.5%                          9.3%
        Normalized
  Adjusted EBITDAR
            margin    17.0%     8.2%     9.4%                         13.2%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."


See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2010
                                (unaudited)


                           Rehabi-                      Elimina-
                           litation Medical             tion of
                 Inpatient Therapy  Staffing  Other &  Affiliated Consoli-
                 Services  Services Services  Corp Seg  Revenue    dated
                 --------  --------  -------  --------  --------  --------
Nonaffiliated
 revenue         $842,248  $ 59,381  $46,231  $     14  $      -  $947,874
Affiliated
 revenue                -    42,187      640         -   (42,827)        -
                 --------  --------  -------  --------  --------  --------
  Total revenue  $842,248  $101,568  $46,871  $     14  $(42,827) $947,874
                 --------  --------  -------  --------  --------  --------

Income (loss)
 from continuing
 operations      $ 76,771  $  7,797  $ 3,283  $(67,084) $      -  $ 20,767
Income tax
 expense                -         -        -    14,431         -    14,431
Interest, net       5,517         -       (1)   18,236         -    23,752
Depreciation and
 amortization      22,698       311      362     1,636         -    25,007
                 --------  --------  -------  --------  --------  --------

  EBITDA         $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Loss on sale of
 assets, net            -         -        -         -         -         -
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(32,781) $      -  $ 83,957

Center rent
 expense           36,709       240      413         -         -    37,362
                 --------  --------  -------  --------  --------  --------

  Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(32,781) $      -  $121,319
                 ========  ========  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA        $104,986  $  8,108  $ 3,644  $(30,533) $      -  $ 86,205
  Normalized
   Adjusted
   EBITDAR       $141,695  $  8,348  $ 4,057  $(30,533) $      -  $123,567


  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          8.9%
 Adjusted EBITDAR
           margin    16.8%      8.2%     8.7%                         12.8%
       Normalized
  Adjusted EBITDA
           margin    12.5%      8.0%     7.8%                          9.1%
       Normalized
         Adjusted
   EBITDAR margin    16.8%      8.2%     8.7%                         13.0%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                 For the Three Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $416,451  $26,155  $26,097  $     10  $      -  $468,713
Affiliated revenue       -   18,360      563         -   (18,923)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $416,451  $44,515  $26,660  $     10  $(18,923) $468,713
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 38,804  $ 3,077  $ 2,289  $(33,359) $      -  $ 10,811
Income tax expense       -        -        -     7,517         -     7,517
Interest, net        3,111        -       (1)    9,355         -    12,465
Depreciation and
 amortization       10,118      131      232       672         -    11,153
                  --------  -------  -------  --------  --------  --------

  EBITDA          $ 52,033  $ 3,208  $ 2,520  $(15,815) $      -  $ 41,946
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $ 52,039  $ 3,242  $ 2,520  $(15,815) $      -  $ 41,986

Center rent
 expense            17,868      114      233         -         -    18,215
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $ 69,907  $ 3,356  $ 2,753  $(15,815) $      -  $ 60,201
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $ 56,339  $ 3,242  $ 2,520  $(15,815) $      -  $ 46,286
  Normalized
   Adjusted
   EBITDAR        $ 74,207  $ 3,356  $ 2,753  $(15,815) $      -  $ 64,501


   Adjusted EBITDA
            margin    12.5%     7.3%     9.5%                          9.0%
  Adjusted EBITDAR
            margin    16.8%     7.5%    10.3%                         12.8%
        Normalized
   Adjusted EBITDA
            margin    13.5%     7.3%     9.5%                          9.9%
        Normalized
  Adjusted EBITDAR
            margin    17.8%     7.5%    10.3%                         13.8%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

  RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS TO ADJUSTED
                        EBITDA and ADJUSTED EBITDAR
                             ($ in thousands)

                  For the Six Months Ended June 30, 2009
                                (unaudited)


                            Rehabi-                     Elimina-
                            litation Medical            tion of
                  Inpatient Therapy  Staffing Other &  Affiliated Consoli-
                  Services  Services Services Corp Seg  Revenue    dated
                  --------  -------  -------  --------  --------  --------
Nonaffiliated
 revenue          $831,687  $51,671  $53,471  $     14  $      -  $936,843
Affiliated revenue       -   36,576    1,123         -   (37,699)        -
                  --------  -------  -------  --------  --------  --------
  Total revenue   $831,687  $88,247  $54,594  $     14  $(37,699) $936,843
                  --------  -------  -------  --------  --------  --------

Income (loss) from
 continuing
 operations       $ 80,598  $ 5,966  $ 4,310  $(68,460) $      -  $ 22,414
Income tax expense       -        -        -    15,575         -    15,575
Interest, net        6,322       (2)      (1)   18,872         -    25,191
Depreciation and
 amortization       19,845      259      422     1,349         -    21,875
                  --------  -------  -------  --------  --------  --------

  EBITDA          $106,765  $ 6,223  $ 4,731  $(32,664) $      -  $ 85,055
Loss on sale of
 assets, net             6       34        -         -         -        40
                  --------  -------  -------  --------  --------  --------

  Adjusted EBITDA $106,771  $ 6,257  $ 4,731  $(32,664) $      -  $ 85,095

Center rent
 expense            35,872      229      477         -         -    36,578
                  --------  -------  -------  --------  --------  --------

  Adjusted
   EBITDAR        $142,643  $ 6,486  $ 5,208  $(32,664) $      -  $121,673
                  ========  =======  =======  ========  ========  ========

  Normalized
   Adjusted
   EBITDA         $111,071  $ 6,257  $ 4,731  $(32,664) $      -  $ 89,395
  Normalized
   Adjusted
   EBITDAR        $146,943  $ 6,486  $ 5,208  $(32,664) $      -  $125,973


   Adjusted EBITDA
            margin   12.8%     7.1%     8.7%                          9.1%
  Adjusted EBITDAR
            margin   17.2%     7.3%     9.5%                         13.0%
        Normalized
   Adjusted EBITDA
            margin   13.4%     7.1%     8.7%                          9.5%
        Normalized
  Adjusted EBITDAR
            margin   17.7%     7.3%     9.5%                         13.4%

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
 "Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

See normalizing adjustments in the table "Normalizing Adjustments -
 Quarter Comparison."



                Sun Healthcare Group, Inc. and Subsidiaries
                      Selected Operating Statistics
                          Continuing Operations


                            For the                     For the
                      Three Months Ended           Six Months Ended
                           June 30,                    June 30,
                    ----------------------      ----------------------
                      2010          2009          2010          2009
                    --------      --------      --------      --------
Consolidated
 Company

Revenues -
 Non-affiliated (in
 thousands)
  Inpatient
   Services         $421,720      $416,451      $842,248      $831,687
  Rehabilitation
   Therapy Services   30,017        26,155        59,381        51,671
  Medical Staffing
   Services           22,875        26,097        46,231        53,471
  Other - non-core
   businesses              6            10            14            14
                    --------      --------      --------      --------
    Total           $474,618      $468,713      $947,874      $936,843
                    ========      ========      ========      ========


Revenue Mix -
 Non-affiliated (in
 thousands)
  Medicare          $141,520  30% $137,863  29% $283,701  30% $279,739  30%
  Medicaid           190,596  40%  188,030  40%  379,920  40%  369,480  39%
  Private and Other  113,475  24%  112,784  24%  225,881  24%  227,282  24%
  Managed Care /
   Insurance          24,045   5%   25,789   6%   48,458   5%   52,198   6%
  Veterans             4,982   1%    4,247   1%    9,914   1%    8,144   1%
                    -------- ---  -------- ---  -------- ---  -------- ---
    Total           $474,618 100% $468,713 100% $947,874 100% $936,843 100%
                    ======== ===  ======== ===  ======== ===  ======== ===



Inpatient Services
 Stats

 Number of centers:      202           202           202           202
 Number of
  available beds:     22,427        22,450        22,427        22,450
 Occupancy %:           86.7%         87.8%         87.1%         88.2%


 Payor Mix % based
  on patient days:
   Medicare - SNF
    Beds                15.3%         15.7%         15.4%         16.1%
   Managed care /
    Ins. - SNF Beds      4.0%          4.1%          4.0%          4.2%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     19.3%         19.8%         19.4%         20.3%
                    --------      --------      --------      --------
  Medicare              14.0%         14.3%         14.1%         14.7%
  Medicaid              62.1%         60.9%         62.1%         60.4%
  Private and Other     19.1%         20.0%         18.9%         20.0%
  Managed Care /
   Insurance             3.6%          3.8%          3.7%          3.9%
  Veterans               1.2%          1.0%          1.2%          1.0%

 Revenue Mix % of
  revenues:
   Medicare - SNF
    Beds                32.1%         32.6%         32.3%         33.2%
   Managed care /
    Ins. - SNF Beds      6.0%          6.5%          6.1%          6.6%
                    --------      --------      --------      --------
       Total SNF
        skilled mix     38.1%         39.1%         38.4%         39.8%
                    --------      --------      --------      --------
  Medicare              32.4%         32.1%         32.6%         32.7%
  Medicaid              45.2%         45.1%         45.1%         44.4%
  Private and Other     15.6%         15.6%         15.4%         15.7%
  Managed Care /
   Insurance             5.6%          6.2%          5.7%          6.2%
  Veterans               1.2%          1.0%          1.2%          1.0%


 Revenues PPD:
  LTC only Medicare
   (Part A)         $ 464.00      $ 454.44      $ 464.99      $ 452.37
  Medicare Blended
   Rate (Part A &
   B)               $ 504.18      $ 494.37      $ 503.24      $ 489.93
  Medicaid          $ 173.30      $ 171.77      $ 173.19      $ 170.25
  Private and Other $ 185.66      $ 175.27      $ 185.99      $ 176.10
  Managed Care /
   Insurance        $ 367.89      $ 376.44      $ 365.84      $ 375.17
  Veterans          $ 240.63      $ 234.73      $ 242.86      $ 227.45


Rehab contracts

 Affiliated              131           121           131           121
 Non-affiliated          335           326           335           326

 Average Qtrly
  Revenue per
  Contract          $    110      $    100      $    109      $     99
  (in thousands)



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

               NORMALIZING ADJUSTMENTS - QUARTER COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - 2nd QUARTER 2010
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported 2nd
 QUARTER 2010    $474,618 $60,550 $41,740 $17,403 $10,268 $  (295) $ 9,973
       Percent of
         Revenue             12.8%    8.8%    3.7%    2.2%   -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs                 -   2,248   2,248   2,248   1,326       -    1,326
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2010    $474,618 $62,798 $43,988 $19,651 $11,594 $  (295) $11,299
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.2%    9.3%    4.1%    2.4%   -0.1%     2.4%

Diluted EPS:
      As Reported                                 $  0.23 $ (0.01) $  0.22
    As Normalized                                 $  0.26 $ (0.01) $  0.25


                               AS REPORTED - 2nd QUARTER 2009
                 ---------------------------------------------------------
                                                  Income
                                                   from
                                                  Contin-
                                                   uing
                         Adjusted Adjusted         Opera-             Net
                 Revenue  EBITDAR  EBITDA Pre-tax  tions  Disc Ops  Income
                 -------- ------- ------- ------- ------- -------  -------

As Reported - 2nd
 QUARTER 2009    $468,713 $60,201 $41,986 $18,328 $10,811 $  (715) $10,096
       Percent of
         Revenue             12.8%    9.0%    3.9%    2.3%   -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs                 -   4,300   4,300   4,300   2,537     348    2,885
                 -------- ------- ------- ------- ------- -------  -------

Normalized As
 Reported - 2nd
 QUARTER 2009    $468,713 $64,501 $46,286 $22,628 $13,348 $  (367) $12,981
                 ======== ======= ======= ======= ======= =======  =======
       Percent of
         Revenue             13.8%    9.9%    4.8%    2.8%   -0.1%     2.8%

Diluted EPS:
      As Reported                                 $  0.25 $ (0.02) $  0.23
    As Normalized                                 $  0.30 $     -  $  0.30

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.



                SUN HEALTHCARE GROUP, INC. AND SUBSIDIARIES

            NORMALIZING ADJUSTMENTS - YEAR TO DATE COMPARISON
                  (in thousands, except per share data)


                               AS REPORTED - SIX MONTHS 2010
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2010          $947,874 $121,319 $83,957 $35,198 $20,767 $   (596) $20,171
     Percent of
       Revenue              12.8%    8.9%    3.7%    2.2%    -0.1%     2.1%

Normalizing
 Adjustments:

 Separation
  transaction
  costs               -    2,248   2,248   2,248   1,326        -    1,326
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2010   $947,874 $123,567 $86,205 $37,446 $22,093 $   (596) $21,497
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.0%    9.1%    4.0%    2.3%    -0.1%     2.3%

Diluted EPS:
    As Reported                                  $  0.47 $  (0.01) $  0.46
  As Normalized                                  $  0.50 $  (0.01) $  0.49


                               AS REPORTED - SIX MONTHS 2009
                 ---------------------------------------------------------
                                                 Income
                                                  from
                                                 Contin-
                                                  uing
                        Adjusted Adjusted         Opera-             Net
               Revenue   EBITDAR  EBITDA Pre-tax  tions   Disc Ops  Income
               -------- -------- ------- ------- -------- -------  -------

As Reported -
 Six Months
 2009          $936,843 $121,673 $85,095 $37,989 $22,414 $ (2,075) $20,339

     Percent of
       Revenue              13.0%    9.1%    4.1%    2.4%    -0.2%     2.2%

Normalizing
 Adjustments:

 Prior periods'
  self-insurance
  costs               -    4,300   4,300   4,300   2,537      348    2,885
               -------- -------- ------- ------- ------- --------  -------

Normalized As
 Reported - Six
 Months 2009   $936,843 $125,973 $89,395 $42,289 $24,951 $ (1,727) $23,224
               ======== ======== ======= ======= ======= ========  =======
     Percent of
       Revenue              13.4%    9.5%    4.5%    2.7%    -0.2%     2.5%

Diluted EPS:
    As Reported                                  $  0.51 $  (0.05) $  0.46
  As Normalized                                  $  0.57 $  (0.04) $  0.53

See definitions of Adjusted EBITDA and Adjusted EBITDAR in the table
"Reconciliation of Net Income to Adjusted EBITDA and Adjusted EBITDAR."

Normalizing adjustments are transactions or adjustments not related to
ongoing operations and consist of Separation transaction costs and prior
periods' self-insurance costs.

Since normalizing adjustments are not measurements determined  in
accordance with U.S. generally accepted accounting principles and are thus
susceptible to varying calculations and interpretations, the information
presented herein may not be comparable to other similarly described
information of other companies.

NASHVILLE, TN–(Marketwire – July 28, 2010) – In conjunction with Vanguard Health Systems,
Inc.’s 2010 Fourth Quarter and Year-End Earnings press release, you are
invited to listen to its conference call that will be broadcast live over
the Internet with senior management of Vanguard discussing the operating
results.

WHAT:    Vanguard Health Systems, Inc.'s 2010 Fourth Quarter and Year-End
         Earnings Conference Call on the Web

WHEN:    Thursday, August 26, 2010 at 11:00 a.m. Eastern time

WHERE:   http://www.vanguardhealth.com or
         http://www.visualwebcaster.com/event.asp?id=71303

HOW:     Live over the Internet -- Simply log on to the web at one of the
         addresses above.  If you connect through www.vanguardhealth.com,
         select the "Latest News" link on the Investor Relations page.

Vanguard Health Systems, Inc. will release its 2010 fourth quarter and
year-end operating results on Wednesday, August 25, 2010, after 4:00 p.m.
Eastern time. The Company’s earnings press release will be posted under
the “Latest News” link on the Investor Relations page of the Company’s web
site www.vanguardhealth.com.

Vanguard Health Systems, Inc. owns and operates 15 acute care hospitals and
complementary facilities and services in Chicago, Illinois; Phoenix,
Arizona; San Antonio, Texas and Massachusetts.

If you are unable to participate during the live Webcast, the call will be
archived on our web site www.vanguardhealth.com. To access the replay,
click on the “Latest News” link on the Investor Relations page of our web
site.

LOS GATOS, CA–(Marketwire – July 28, 2010) –  SCI Solutions^®, the premier Access Management solution provider for healthcare, today announced the release of a new version (v33) of its powerful, rules-based, enterprise scheduling solution, Schedule Maximizer®.

Schedule Maximizer (v33) features numerous updates, including enhanced scheduling functionality that incorporates insurance verification/eligibility rules affecting consumer driven health plans. The revamped Encounter Module, Multi-entity Rules and Worklist features further simplify and streamline a hospital’s pre-registration/registration processes.

Additionally, Schedule Maximizer’s reporting capabilities have been expanded to include a new report that provides the total number of patients that are scheduled for a particular date or date range. This report is a quick and efficient method to assist in Registration clerk staffing needs for a facility and/or a particular location/clinic in that facility.

According to Kristy Roesner, SCI’s SVP of Product Development, “The enhancements in Schedule Maximizer (v33) reflect SCI’s position as innovators in the Healthcare Information Technology arena.” She continued, “We are proud of this version’s updates as they represent significant enhancements that expand its overall capabilities as an insurance verification and pre-registration process improvement tool.”

SCI Solutions, through its Software as a Service (SaaS) model, provides a full complement of front-end patient access and revenue cycle tools that include comprehensive enterprise scheduling and registration, sophisticated workflow to manage a hospital’s orders, scheduling and pre-encounter revenue cycle requirements. Additionally, SCI provides customer self-service solutions that help physicians and patients interact seamlessly with your organization for all their access-related needs. SCI’s Access Management offerings fall into the following categories:

• Order Facilitator^®
• Schedule Maximizer^®
• Revenue Accelerator^®
• Consumer Portal
• Provider Portal

About SCI Solutions

SCI Solutions is transforming healthcare Access Management with web-based products and services that facilitate the efficient and secure exchange of clinical and financial information between patients, physicians and healthcare facilities. SCI provides a variety of products and self-service portals that help physicians and patients interact easily and at their convenience for many of their access-related needs. From a hospital’s clinical departments, to its financial executives, to its physicians SCI improves their effectiveness while making the patient’s service experience first class.

Founded in 1999, SCI Solutions is headquartered in Los Gatos, Calif. with additional offices in Tucson, Ariz., Pensacola, Fla. and employees throughout the United States. For more information about SCI Solutions, visit www.scisolutions.com.

Click here to see all recent news from this company

NATICK, MA–(Marketwire – July 28, 2010) –  To ensure downtime access to current patient data after moving to electronic medical records (EMRs) and electronic medication administration records (eMARs), Hancock Regional Hospital in Greenfield, IN implemented NetSafe, Interbit Data‘s downtime protection and business continuance solution. NetSafe downloads up-to-the-minute patient data and records from the hospital’s MEDITECH Healthcare Information System (HCIS) and provides access to it from local machines, allowing clinicians to obtain the information they need where they need it whenever the system or network goes down. With NetSafe, critical patient data is always available and the hospital assures patient safety and the delivery of uninterrupted care.

“NetSafe is a terrific safety net if the HCIS, a server or the network goes down,” states Doug Hogue, information analyst at Hancock Regional Hospital. “It’s one of those tools we hope to never have to use, but if and when we do need to rely on it, we have complete trust it will perform superbly. With NetSafe, we have peace of mind knowing that the latest eMARs and other important patient information are in a location that we can access when that information is needed.”

A one-minute video on the downtime protection and business continuance benefits of NetSafe is available at: http://interbitdata.com/business-continuance/netsafe/

Using NetSafe, Hancock Regional Hospital downloads updates of the eMARs every hour to ensure that clinicians can obtain the most up-to-date medication information on their patients whenever the system is unavailable. Electronic physician orders are updated twice per day and in PDF format, allowing staffers at registration desks to bring up and view the orders easily. Patient profiles, surgery schedules and out-patient schedules are also downloaded and updated. Physicians’ practices use NetSafe as well to back up their schedules. 

Since Hancock Regional Hospital started using NetSafe in 2007, it has had four planned downtimes due to MEDITECH updates. It has had no unplanned downtimes as yet. 

“If an unplanned downtime were to happen, we’re confident that we’re ready,” confirms Hogue. “NetSafe has performed flawlessly during the downtimes Hancock Regional Hospital has experienced so far, providing clinicians with whatever information they needed during those times.”

Over the three-plus years of using NetSafe, Hancock Regional Hospital’s experience with it has been nothing but positive.

“I love it, it’s a great product,” affirms Hogue. “NetSafe is easy to use, and other than normal server maintenance, I don’t need to do anything to it.”

More information on NetSafe can be obtained at http://interbitdata.com/business-continuance/netsafe/.

About Hancock Regional Hospital
Hancock Regional Hospital in Greenfield, IN is a full-service primary care facility serving the residents in east-central Indiana. The hospital offers a state-of-the-art surgery department, 24-hour emergency services, progressive and critical care, occupational health, a transitional care unit, a total oncology program, and comprehensive inpatient and outpatient services, including the more specialized Diabetes Center and Center for Wound Healing.

About Interbit Data
Founded in 1997 and named to the 2009 Inc. 5000 list of America’s fastest growing companies, Interbit Data helps healthcare organizations deliver better, more consistent patient care with secure, reliable and cost-effective software solutions that improve operational efficiency. The company’s information distribution products deliver information securely over the Internet in multiple formats, such as fax, print, email, encrypted file or HL7 message format, and integrate it easily into physicians’ practice EMRs. Interbit Data’s business continuance products give healthcare providers continuous access to patient data in the event of a network or system outage. Interbit Data products are used by more than 650 MEDITECH^® customers worldwide. For more information about Interbit Data and its NetSolutions products, visit the company Website at www.interbitdata.com.

Click here to see all recent news from this company

WINNIPEG, MANITOBA–(Marketwire – July 28, 2010) – DiaMedica Inc., (TSX VENTURE:DMA) today announces the initiation of the Company’s autoimmune program with the success of DM-99 for the treatment of rheumatoid arthritis and other autoimmune diseases.

DM-99 was found to reduce joint swelling by up to 90% (p<0.001) in a collagen induced animal model of rheumatoid arthritis (RA) during the peak of the disease. A single dose of the protein DM-99 administered at the first signs of RA symptoms delayed the onset and severity of the disease. Furthermore, treatment given every forth day appears to have halted the autoimmune attack altogether. 

“We believe that DM-99 is able to activate or increase the number of regulatory T cells (Tregs), which plays a vital role in suppressing the autoimmune attack in a wide range of autoimmune diseases,” commented Dr. Mark Williams, DiaMedica’s Vice President Research.

In a delayed hypersensitivity model, skin inflammation was reduced by 67% (p<0.05) and could be prevented for up to 14 days following a single administration of DM-99. DM-99 also delayed skin graft rejection by several days (p<0.05).

“Based on the ability of DM-99 to modulate the autoimmune attack in several autoimmune diseases, we will be starting a study shortly to determine if our more active form of DM-99, DM-199, can halt or slow the autoimmune attack in type I diabetes. DM-199, may be the only compound that both proliferates beta cells and protects them against the autoimmune attack in type I diabetes,” stated Rick Pauls, President and CEO of DiaMedica.

About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders. The Company’s type 2 diabetes program is based on a critical liver nerve signaling mechanism involved in enhancing insulin sensitivity after meal consumption. Two of DiaMedica’s products, DM-71 and DM-99, have previously demonstrated human efficacy in lowering blood sugar levels in people diagnosed with type 2 diabetes based on this novel nerve signaling mechanism.

DiaMedica has expanded its DM-199 recombinant protein program into neurological and autoimmune disorders. The Company has demonstrated that DM-99, the naturally occurring form of DM-199, confers neural protection (protects brain cells) and triggers neural stem cell proliferation (creates brain cells) for the treatment of numerous neurological disorders including Alzheimer’s disease. DiaMedica is listed on the TSX Venture Exchange under the trading symbol “DMA”.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, the “forward-looking statements“). These forward-looking statements relate to, among other things, DiaMedica’s objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Specifically, this press release contains forward-looking statements regarding matters such as, but not limited to, the anticipated use of proceeds from the Offering, management’s assessment of DiaMedica’s future plans, information with respect to the advancement of DiaMedica’s research and development programs, and DiaMedica’s other estimates and expectations. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: uncertainties and risks related to our research and development programs, the availability of additional financing, risks and uncertainties relating to the anticipated use of proceeds, changes in debt and equity markets, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, the cost and supply of raw materials, management of growth, effects of insurers’ willingness to pay for products, risks related to regulatory matters and risks related to intellectual property matters. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release, as well as under the heading “Risk Factors” contained in DiaMedica’s 2009 annual information form. DiaMedica cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on DiaMedica’s forward-looking statements to make decisions with respect to DiaMedica, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Such forward-looking statements are based on a number of estimates and assumptions, which may prove to be incorrect, including, but not limited to, assumptions regarding the availability of additional financing for research and development companies, and general business and economic conditions. These risks and uncertainties should be considered carefully and investors and others should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, DiaMedica cannot provide assurance that actual results will be consistent with these forward-looking statements. DiaMedica undertakes no obligation to update or revise any forward-looking statement. Additional risk factors, factors which could cause actual results to differ materially from expectations, and assumptions relating specifically to our acquisition of Sanomune may be found in our press releases dated February 18, 2010 and April 20, 2010.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 28, 2010) –

TO: Investors, Analysts and Journalists

WHAT: NicOx S.A. will release its 2010 half year financial results on July
30 before the opening of the market trading in France and will host a
conference call at 3:00 pm CET.

WHO: Michele Garufi, Chairman and CEO

Eric Castaldi, Chief Financial Officer

Gavin Spencer, VP Business Development

WHEN: Friday July 30 – 3:00 pm CET (2:00 pm UK – 9:00 am EST)

Phone number: +44 (0)20 7138 0845 or +1 212 444 0895 (for conference call
and Q&A session).

A presentation will be available on NicOx’s website: www.nicox.com.

A replay of the conference call will be available from July 30 at 6:00 pm
CET until August 6 midnight. To listen to the replay, dial +44 (0) 20 7111
1244 or +1 347 366 9565 – Access code: 3771435?

Thanks to confirm your participation to Irène Lalande, Investor and
Media Relations Coordinator. Tel: +33 (0)4 97 24 53 11 / [email protected]

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the U.S. Food and Drug
Administration (FDA) provided a Complete Response Letter to the New Drug
Application (NDA) for naproxcinod stating that it does not approve the
naproxcinod application. The naproxcinod Marketing Authorization
Application (MAA) submitted by NicOx in December 2009 is currently under
review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This information is provided by HUGIN

SALT LAKE CITY, UT–(Marketwire – July 28, 2010) –  AdvancedMD^® Software, Inc., the leader in all-in-one, web-based practice management, electronic health record (EHR), and billing applications for medical practices and medical billing services, today announced that PhySource Solutions, Inc., an AdvancedMD AdvancedBiller^® partner, has achieved two significant milestones in client service and company growth. On average, over the past 12 months the company’s new clients have reduced outstanding accounts receivable balances considered uncollectible from 30% to 2%. This caliber of results has fueled more than 100% growth in the company’s client list over the past year.

With the prolonged economic downturn, PhySource Solutions has seen many medical group clients struggle to keep accounts receivable within acceptable limits. Typical new clients have more than 30% of their receivables in the 90-day or greater category, which is considered mostly uncollectible. After only six months with PhySource Solutions, new medical practice clients see accounts receivable numbers come into line with MGMA industry benchmarks. PhySource clients realize on average 80% of claims in the current category (within 30 days) and only 10% at 90 days or more.

“Bringing accounts receivable in line is an exciting thing for clients, particularly when they see the impact it can have on revenues and profitability,” said Zina Kacha, director of business relations for PhySource Solutions. “In a scenario like this, clients regularly see at least a 15 percent improvement in revenues and profits.” PhySource founders Patricia Rosbrook and Kacha each have more than 25 years of experience in medical billing, financial analysis, consulting and executive management in a variety of healthcare related companies.

Largely as a result of the magnitude of payment improvement PhySource regularly achieves for clients, the company recently signed a new contract to provide billing services to San Diego Heart and Vascular, a seven provider Cardiology group serving the San Diego region. “The number one reason we switched [to PhySource Solutions] was that Dr. Salami’s trial EOB reports came in showing line after line of ‘paid’ instead of the multiple zeros we saw under the previous system,” said Mary Augenbaugh, practice administrator for San Diego Heart and Vascular.

As a participant in the AdvancedBiller partner network, PhySource Solutions runs its revenue management service on the AdvancedMD Software-as-a-Service platform, featuring a continuously updated payer rules engine, connectivity to more than 1,400 payers and instant software updates. In a large measure due to these AdvancedMD automation tools for claims management and the system’s robust reporting capabilities, PhySource was able to double its business last year and expects to double again next year. By avoiding stacks of paper, unwieldy filing systems, and tedious work in tracking down details, the firm has built a highly effective claims management system that can be quickly scaled up to handle the significant growth PhySource is experiencing.

“AdvancedMD is quality backed by functionality that equals manageability,” said Kacha. “It allows us to compile, maintain and track the mountains of data endemic to our industry in a way that I’ve never seen before. It’s the WOW of medical billing software.”

“AdvancedMD has made a corporate commitment that we will not compete with our billing service provider customers,” said Bill Stone, vice president and general manager of AdvancedMD Billing Services Partner Division. “Our relationship with PhySource Solutions is a prime example of this philosophy in action. We couldn’t be more pleased with their growth and success, and we remain committed to helping them grow their client base.” The AdvancedBiller program not only provides medical billing services with a leading technology platform, it provides lead generation opportunities to partners and sales support to help the billing service accelerate sales.

AdvancedMD Resources

• Learn more about PhySource Solutions: http://advancedmd.com/resources/medical-billing-software-case-study/
• Learn about the AdvancedBiller program: www.advancedbiller.com
• Learn about SaaS-based medical office software

About PhySource Solutions, Inc.

PhySource Solutions is a dynamic company located in San Diego, California. PhySource Solutions uses extensive surgical coding and medical billing knowledge to deliver comprehensive Revenue Cycle Management Services to its providers. The company has deep specialty specific experience and proficiencies for cardiology surgeon groups, helping their providers optimize their bottom line by providing a fully integrated Revenue Cycle Management service that includes surgical coding, medical billing, front-end training and financial analysis and reports. For more information, please visit www.physourcesolutions.com.

About AdvancedMD Software

AdvancedMD provides a market leading Software-as-a-Service (SaaS) electronic health record (EHR) and practice management (PM) software platform delivered to more than 10,000 providers and 300 medical billing service providers nationwide. As a complete Medical Practice Optimization solution, the product combines the clinical with the financial to improve workflow and revenue capture. The AdvancedMD solution includes a certified EHR, patient portal, scheduling, electronic eligibility verification, electronic prescribing, and mobile access capabilities for the practice. It provides sophisticated, efficient claims processing, denial tracking and revenue management for the billing professional. Processing more than 1M claims per month through its clearinghouse, the company is able to identify payer rule changes quickly and continuously adjust the software to reflect those changes, yielding first-pass claim acceptance rates of 95 percent or better, compared to the national average of 70 percent. For more information, please visit www.advancedmd.com.

*AdvancedBiller is a registered trademark of AdvancedMD

BETHESDA, MD–(Marketwire – July 28, 2010) –  GetWellNetwork, Inc., the leader in interactive patient care, today welcomed new customer Adventist Medical Center-Hanford located in Hanford, California. The hospital will implement the GetWellNetwork solution hospital-wide and go live this fall. 

Adventist Health/Central Valley Network is the first organization in the region to offer the GetWellNetwork interactive patient care system to its patients. The GetWellNetwork solution enables clinicians and hospital staff to more actively engage patients and their families in the care process by using the bedside TV to provide them with information specific to their condition, medication, treatment and discharge procedures.

“GetWellNetwork goes beyond patient entertainment to create an environment that empowers patients and their families to be truly involved in their care,” said Kristen Johnson, MHA, BSN, RN, vice president of Patient Care Services, Adventist Medical Center-Hanford. “Hospitals that have implemented the GetWellNetwork solution have raised patient satisfaction, improved patient safety and quality, and reduced hospital costs. We are excited to offer the GetWellNetwork system in our hospital.”

In the first phase, the hospital will offer patients satellite TV channels, HBO movies, 74 games, high quality Internet browsing capabilities, as well as a variety of hospital information and resources such as visiting hours, cafeteria menu, maps, chaplain services, hospital services and staff information.

In the second phase of the implementation, beginning in 2011, the hospital will look to offer additional features such as:

• Personalized information on the home screen such as the patient’s primary physician, the nurse on duty and other clinical providers, in English and Spanish;

• Patient Pathways to actively send messages to patients to complete medication teaching, answer patient satisfaction surveys, learn about discharge instructions, and more; 

• Patients may also be asked to “nominate” their favorite nurse or doctor through an electronic comment card prior to discharge; and

• The hospital expects to implement the pain management capability that prompts patients to rate their level of pain at set intervals, and program the system to turn on healing video content such as soothing nature scenes.

About GetWellNetwork
GetWellNetwork, Inc. uses the bedside TV to entertain, educate and empower hospital patients and caregivers to be more actively engaged in their care. This patient-centered approach improves both satisfaction and outcomes for patients and hospitals. GetWellNetwork is the leader in interactive patient care solutions and exclusively endorsed by the American Hospital Association. More information about GetWellNetwork can be found at www.GetWellNetwork.com.

Click here to see all recent news from this company

DUBAI, UNITED ARAB EMIRATES–(Marketwire – July 28, 2010) – A survey published today by a prominent Medical Tourism consultant has revealed that 94% of medical tourism industry insiders believe their sector of the industry has yet to reach its full potential. The report, which can be viewed on-line at www.DrPrem.com, shows that confusion, a lack of information and fear about complications following surgery are the main reasons for patient reluctance to cross international borders for health services.

“The medical tourism industry is going through an exciting phase where international and intra-regional activities are taking places within this sector of the health market,” said Dr. Prem Jagyasi, architect of the survey and an experienced consultant in the healthcare travel sector. “The responses received clearly revealed that there is an overwhelming perception among industry leaders that there is so much more that can be achieved,” he added.

The findings are particularly interesting as more than 35 countries were identified as important medical tourism destinations. Of the 35 countries, India was ranked as the number one popular destination, with Thailand and Singapore positioned at second and third places respectively. The United States had a surprise ranking at number four.

“The Asian and Far Eastern countries are well-established medical tourism destinations, so the top three placing were expected,” said Dr. Jagyasi. “The United States came in at number four, which clearly indicate Medical Tourism is not all about low price affairs. The quality of healthcare services at a destination is deemed to be of utmost importance. Latin American and European countries were in the top ten, indicating that medical tourism is not dominated by one continent or geography – it’s a truly global industry” added Dr Prem Jagyasi who is also Honorary Chief Strategy Officer of Medical Tourism Association, world’s biggest non-profit organization of this particular industry, based in Florida US with representative office across the world.

The purpose of the health tourism survey, according to Dr. Jagyasi, was to gain valuable insights into aspects of medical tourism from professionals who are closely involved with the industry. Ninety-five per cent of the survey’s participants identified themselves as being either directly or indirectly involved with healthcare travel in the scope of their work and the resulting information supplied by these insiders revealed many important facts concerning this specialised sector; including its terms, trends, status, opportunities and challenges. The knowledge gleaned from the survey will be used to promote this sector of the healthcare industry and will provide important content for a soon-to-be published guidebook for consumers who are considering undertaking treatment abroad.

“One of the survey questions enquired why the respondents thought that there may be a reluctance in some consumers to participate in healthcare tourism and the main responses we received were that they may have concerns about complications, experience confusion over aspects of available services, be uninformed and find the option complicated,” said Dr. Jagyasi. “This is important information, as it clearly shows that education is a vital component in allowing us to facilitate medical tourism to reach its greatest potential. If we can allay people’s fears about foreign treatments and guide potential health tourists with information on what to expect and important advice on visa and travel issues, then we will be providing a vital service and as well as giving a welcome boost to the region’s health sector,” he added. 

Hence, Dr Prem Jagyasi has taken initiative to publish a guidebook. He has high hopes that it will become a handy reference tool for those wanting to know more about the intricacies of travelling across borders for healthcare services. The book is the latest achievement in his specialist interest in medical tourism and he has visited more than 20 countries and spoken at 30 international congresses relating to this sector of the healthcare industry. “Medical tourism can offer huge benefits in terms of quality of service and its affordability, in fact, the survey revealed that industry leaders view these as being its key drivers,” he said. “The industry is set to grow enormously over the next two decades as more and more destinations open up to patients from overseas,” he added.

The medical tourism survey was conducted on-line and contained questions that had been developed over a six month period and based on intensive research. The qualitative assessment was sent to medical tourism professionals in North America, South America, Africa, Europe, the Middle East and Gulf regions, Asia and the Far East. It found that medical tourism facilitators are in a prime position to capitalise on the promising opportunities offered by this sector of the health market; with 88% of respondents agreeing that role of facilitator – those agencies providing health-related travel services – are either important or very important in this segment.

Selected Observations from Survey Results (Download complete report from www.DrPrem.com )

• The preferred term from respondents for this particular sector of the healthcare industry is ‘Medical Tourism’, with 35% selecting this option. ‘Global Healthcare’ was the next most popular term at 22%, with ‘Health Tourism’ running a close third at 21%. “Medical Travel’ was identified by 10% of respondents as their preferred description, with ‘Healthcare Travel’ and ‘Value Medical Travel’ both at 6%.

• 35 countries in total were identified as being medical tourism destinations; which were (in alphabetical order: Argentina, Australia, Belgium, Brazil, Caribbean, China, Costa Rica, Cuba, France, Germany, Hungary, India, Israel, Japan, Jordan, Malaysia, Mexico, Morocco, New Zealand, Panama, Philippines, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Tunisia, Turkey, UAE, UK and USA.

• India, Thailand and Singapore were ranked first, second and third as the most popular medical tourism destinations respectively. The United States was placed at number four.

• 94% of respondents agreed with a statement that medical tourism was yet to reach its full potential.

• The four most popular reasons given for why patients travel abroad to receive medical treatment were ‘Affordability (costly in home country)’ at 88%, ‘Accessibility (waiting period is high)’ at 66% ‘Better quality (care and support services are better quality than the home country) at 38% and ‘Availability (not available in home country) at 46%.

• The four most popular reasons given for patients being unwilling to avail themselves of treatment abroad were ‘Concern about complications’ at 50%, ‘Confusion’ at 46%, patients being ‘Uninformed’ at 44% and finding the option ‘Complicated’ at 39%

• The top four challenges to the medical tourism industry were identified as being ‘Accessing reliable information’ at 59%, ‘Too many newcomers jumping on the medical tourism bandwagon, not experienced or understanding of the industry’ at 54%, ‘Lack of pre and post operative care arrangements at 52% and ‘Complicated intra-country laws and legal procedures’ at 49%.

• The top three reasons identified that are essential components of a good medical tourism destination were ‘Quality standards of healthcare and wellness services’ which was marked by 51% of respondents, followed by ‘Accessibility of the destination’ at 30% and ‘Technology, facilities & specialisations available’ at 27%.

• The survey takers were asked why they thought Medical tourism was a new ‘buzzword’ (or more accurately a ‘buzz phrase’). Fifty-six per cent (56%) agreed that it was ‘Because increasing numbers are travelling for healthcare’, with almost the same percentage (55%) also agreeing that it was ‘Because medical tourism benefits a cross section, including governments insurance companies, travel/tourism, healthcare and facilitators’. Fifty-seven per cent (57%) agreed that it was ‘Because it offers value for money’ and 46% said that it was ‘Because big hospitals are promoting it’. 

• The role of facilitators in the industry was deemed by the respondents to be significant (an explanation of facilitators being that they arrange medical tourism either in part or in whole for health tourists). Sixty-one per cent (61%) said that facilitators were ‘Very important’, 27% said that they were ‘Important’, 10% regarded them as ‘Optional’ and 2% said that they were ‘Not important’.

About ExHealth:

Motivated by a creative vision and committed to an innovative mission, ExHealth offers a comprehensive array of tailor-made, media-related healthcare services, encompassing Marketing, Public Relations, Conference and Event Management, Design & Publication, Healthcare Tourism Consulting and Medical Management Consulting, all of which are located under one roof at Dubai HealthCare City. ExHealth’s key concern is to perform and execute incomparable solutions for healthcare organisations across all sectors of the industry. Aiming to achieve and surpass its customers’ stated goals, ExHealth is focused on ensuring that its clients’ business has the edge in today’s competitive market place.

About Dr Prem Jagyasi

Dr Prem Jagyasi is a successful entrepreneur and experienced strategic professional. He is a renowned chartered management, healthcare marketing and medical tourism consultant responsible for providing high-profile consultancy services to both government authorities and private healthcare organisations. Dr. Prem Jagyasi’s commitment to developing medical tourism has seen him become a leading figure in the international healthcare tourism world.

Currently, Dr Prem Jagyasi is MD & CEO of ExHealth; a Dubai Health Care City-based firm engaged in offering multi-dimensional healthcare solutions across the international domain. He also serves the Medical Tourism Association — a non-profit organization based in USA – as Honorary Chief Strategy Officer. He is also the Chief Editor of UAE’s leading health magazine, HealthFirst, which is published in association with one of the region’s leading English language daily newspapers.

Direct Download Link

http://www.drprem.com/Medical_Tourism_Research_and_Survey_Report_by_Dr_Prem_Jagyasi.pdf

BOCA RATON, FL–(Marketwire – July 28, 2010) –  David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor Chief Medical Officer Dr. Daniel Weiss will present an abstract of the results of a pilot study to test the ability of Vicor’s PD2i^® nonlinear algorithm to detect acute hypovolemia at the AABB 2010 Annual Meeting. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i^® nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including cardiac death resulting from arrhythmia or pump failure, and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.

Dr. Weiss will present Mild Hemorrhage Results in Observable Changes in Heart Rate Variability (S106-040B) on October 12, 2010 at 3:15pm in room 339/340, during the session entitled Donor Recruitment, Retention and Adverse Events: Hemoglobin and Iron. The AABB Annual Meeting & CTTXPO 2010 will be held at the Baltimore Convention Center on October 9-12, 2010. 

“We’re honored to have Dr. Weiss’s abstract of our hypovolemia study selected for presentation before this prestigious group. We believe the results achieved by the PD2i^® in this small pilot study suggest the prospect of incorporating the PD2i^® nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally. We hope that having the opportunity to share these results with those active in the field of transfusion medicine and cellular technologies worldwide will further opportunities to advance study of the PD2i^® as a noninvasive diagnostic to detect acute hypovolemia, and further our commercialization efforts for the PD2i^®,” stated Mr. Fater.

The study on which the abstract is based was conducted in cooperation with the University of Mississippi Medical Center and Mississippi Blood Services on December 12, 2009 in Smithdale, MS. The goal of the study was to test the ability of Vicor’s PD2i^® nonlinear algorithm to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding. All 18 participants in the pilot study were tested prior to donation to determine a baseline PD2i^® value, and re-tested during and after collection. The average PD2i^® value of participants prior to donation was 2.60; the average PD2i^® value following donation was 1.80. With a P value of 0.001, the study results are highly statistically significant; this indicates a better than 99% probability that the results were not achieved randomly.

The AABB is an international, not-for-profit association representing individuals and institutions involved in the field of transfusion medicine and cellular therapies. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety. AABB membership consists of nearly 2,000 institutions and 8,000 individuals, including physicians, nurses, scientists, researchers, administrators, medical technologists and other health care providers. Members are located in more than 80 countries.

About Vicor Technologies, Inc.
Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i^®). The PD2i^® nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer™, which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes. The PD2i VS™ (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA™ (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i^® nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer
The appearance of name-brand institutions or products in this media release does not constitute endorsement by the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense, the U.S. Government, or the AABB of the information, products or services contained therein.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain FDA approval of our 510(k) submission to secure a claim for the PD2i CA™(Cardiac Analyzer) for risk stratifying congestive heart failure patients at elevated risk of cardiac mortality and our ability to obtain marketing clearance from the FDA for the PD2i VS™ (Vital Sign) for military and civilian applications; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-12

Click here to see all recent news from this company

IRVINE, CA–(Marketwire – July 28, 2010) –  Lantronix, Inc. (NASDAQ: LTRX), a leading provider of secure, remote management, device networking and data center management technologies, today announced the worldwide availability of the EDS1100 and EDS2100 Linux software development kit (SDK), furthering its commitment to Linux and strategy for open source computing. The new SDK allows Linux developers to quickly and easily create value-added applications on the EDS1100/2100. Built on the proven, stable 2.6 Linux kernel, the SDK includes a robust set of components for building secure network-enabled products and applications using Linux, one of the world’s most popular open operating systems. Also included in the announcement are firmware updates for the XPort® Pro Linux SDK and MatchPort® AR Linux SDK, available for download at www.Lantronix.com/downloads. 

The EDS1100 and EDS2100 Linux SDK key improvements include:

• uClinux baseline upgrade (Linux kernel 2.6.29);
• IPv6-ready Certification;
• SDK VMWare VM Image to enable developers to build, deploy, customize and maintain Linux applications in a Windows environment;
• Serial-to-Ethernet with SSL and SSH support sample application.

“While we will continue to offer our customers the tools to develop products using our tried and true operating systems, expanding our Linux offerings extends the capabilities of our products for current customer needs and opens up our products to an exponentially wider audience,” said Daryl Miller vice president of engineering for Lantronix. “Every new product we launch will now support Linux.”

The EDS1100/2100 is also available with Lantronix’ powerful operating system, Evolution OS®, which provides end-users a rich, turnkey option with robust functionality right out of the box.

About EDS1100/2100
The EDS1100 and EDS2100 are unique, hybrid Ethernet terminal/multiport device servers which allow remote access to and management of virtually any IT/networking equipment or edge device such as medical equipment, POS terminals or security equipment. Available with Linux and IPv6 or Lantronix’ powerful Evolution OS, the EDS1100/2100 is the best choice when critical data needs to be remotely and securely accessed anywhere, at any time, via the Internet.

For more details on EDS1100/2100, please visit http://www.lantronix.com/device-networking/external-device-servers/eds1100_eds2100.html or contact [email protected].

The Lantronix blog, http://www.lantronix.com/blog, features industry discussion and updates. To follow Lantronix on Twitter, visit http://www.twitter.com/Lantronix

To receive an RSS feed of all Lantronix’ news, please visit http://www.lewiswire.com/us/lewiswire/Lantronix/c/458 and click on subscribe.

About Lantronix
Lantronix, Inc. (NASDAQ: LTRX) is a global leader of secure communication technologies that simplify remote access, management and control of any electronic device. Its solutions empower businesses to make better decisions based on real-time information, and gain a competitive advantage by generating new revenue streams, improving productivity and increasing efficiency and profitability. Easy to integrate and deploy, Lantronix products remotely connect and control electronic equipment via the Internet; provide secure remote access to firewall-protected equipment; and enable remote management of IT equipment over the Internet. Founded in 1989, Lantronix serves some of the largest security, industrial and building automation, medical, transportation, retail/POS, financial, government, consumer electronics/appliances, IT/data center and pro-AV/signage entities in the world. The company’s headquarters are located in Irvine, Calif. For more information, visit www.lantronix.com.

VANCOUVER, BRITISH COLUMBIA–(Marketwire – July 27, 2010) – ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF)(PINK SHEETS:APCSF) (the “Company”) announces that, as a result of prevailing market conditions, the private placement financing originally announced on April 15, 2010 (and subsequently revised as disclosed in the Company’s news releases of April 28^th and May 28^th), will not be proceeding on the terms disclosed. The Company is proceeding with a smaller private placement of $325,000 to be used for general corporate purposes by the sale of 3,250,000 share purchase units on a private placement basis, pursuant to registration and prospectus exemptions of applicable securities laws and is subject to acceptance by the TSX Venture Exchange, at $0.10 per unit. Each Unit consists of one common share of ALDA and one non-transferable share purchase warrant entitling the holder to acquire one additional common share of ALDA at a price of $0.20 per common share for a period of two (2) years from the date of the issuance of the purchase warrant with an accelerated exercise provision attached to each warrant commencing on the day following the expiry of any applicable hold period on the underlying Common Share, stating that if, for ten consecutive trading days, the closing price of the listed shares of the Company exceeds $0.40 then the exercise period of the warrants will be reduced to a period of 10 days following such trading days. All securities issued will be subject to a four month restricted period and will bear a restrictive legend accordingly.

Insiders of ALDA will be subscribing for 25% of the offering, constituting a related party transaction pursuant to Multilateral Instrument 61-101 and TSX Venture Exchange Policy 5.9 which is exempt from the requirement to obtain an independent valuation pursuant to Section 5.5(b) of MI 61-101 and the requirement to obtain minority shareholder approval pursuant to Section 5.7(1)(b) of MI 61-101. Their participation will be on the same terms as arm’s length investors, and such insiders’ shareholdings in the Company will increase as a result of any such participation. The revised private placement is intended to close within the next week as soon as the requisite approvals of the TSX Venture Exchange are obtained.

The Company also wishes to clarify that a report on the TSX Venture Exchange website on Tuesday, July 20, 2010 that an insider sold 108,500 shares at $0.12 was not correct. The Company has confirmed that the transaction did not involve a current insider of the Company and was incorrectly designated as such on the TSX Venture Exchange website.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T³6^® technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO, ALDA Pharmaceuticals Corp.

The Units, common shares, warrants and the common shares issuable upon exercise of the warrants have not been registered under the United States Securities Act of 1933 (the “Act”) and may not be offered or sold absent registration under the Act or an applicable exemption from the registration requirements thereof. This news release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction or an exemption therefrom.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

DURHAM, NC–(Marketwire – July 27, 2010) –  On the heels of significant Midwest success, Third Degree Advertising is now offering its healthcare-oriented internal communications expertise on a national scale — starting with the East Coast.

“Strong brands start on the inside, and all positive outward change must first be embraced internally,” said Third Degree CEO Roy Page. Third Degree has helped healthcare organizations improve their brands by taking a unique, tailored approach to defining culture and creating opportunities for fruitful conversation between staff and doctors.

One of the key tools for introducing a brand internally is a Culture Book, outlining either a new or updated visual identity as well as the philosophical standards of the strategic branding initiative. “Culture Books can be short and sweet, or comprehensive and corporate,” said Page. 

Jackson County Memorial Hospital
Third Degree worked closely with Jackson County Memorial Hospital to develop their new strategic branding platform, which depended entirely on the buy-in of hospital employees. “This is My Hospital” was launched with an open house event to which staff, patients and community members were invited. Elements of this custom program included an employee Culture Book, a community newsletter, a redeveloped social website, and a Facebook page which helped promote JCMH’s culture both internally and to the community that JCMH serves.

Unity Health Center
Unity Health Center has a strong, community-focused brand. Third Degree developed their positioning: “It starts at the center,” to communicate how patients and employees are at the core of Unity’s commitment to greater health care in the local community. Their internal integrated marketing launch took place in a Unity town-hall style meeting where a brand video, specialty brochure and T-shirts with brand artwork were shared with all levels of staff. The Unity Culture Book, “It Starts with You” informed staff about the new brand and special programs like their teamwork-building paper puzzle pieces and “brag boxes” to recognize co-worker excellence. 

About Third Degree
Third Degree (www.thirddegreeadv.com) fosters more effective doctor-staff communication, and greater patient satisfaction. Third Degree provides strategic marketing research and planning, public relations, media planning and buying, and creative integrated marketing services for print, broadcast, and web-based applications. Based in Oklahoma City, OK and now Durham, NC, the agency works with clients in numerous industries across the U.S.

For more information contact Roy Page at [email protected] or call 1-888-871-3729.

SAN DIEGO, CA–(Marketwire – July 27, 2010) –  SpectraScience, Inc. (OTCBB: SCIE), a San Diego based medical device company, today announced that it was named in the top 50 publicly Traded biotech firms by the American Registry. The award was recognized in the San Diego Daily Transcript. The company’s WavSTAT cancer Screening Technology was also recently featured in a cover story in the June 2010 issue of MTI, as a company to watch that is developing and advancing GI diagnostics and screening technologies. Other companies mentioned in the story include Fuji Photo Optical, Olympus Optical and Smiths Group.

According to the article about 20 million endoscopic procedures are performed annually in the U.S. and key factors driving growth in procedures includes the aging population and increasing prevalence of gastrointestinal disorders.

“One of the most exciting areas of technology development for gastroenterology is enhanced imaging modalities,” says author Staylo. “Researchers are continually looking for new ways to improve the accuracy and diagnostic utility of endoscopic screening methods.”

Jim Hitchin, CEO of SpectraScience, said, “We are pleased to have been named in the top 50 publicly traded biotech firms by the American Registry and to also have received significant attention at this year’s Digestive Disease Week (DDW), which led to this article highlighting our technology for the medical community. This shows that SpectraScience is making a name for itself with its state of the art technology.”

Benefits of WavSTAT Technology

• Doesn’t require physical interpretation of screening results, but gives results in objective, standardized format
• Both a therapeutic and diagnostic device so it can remove abnormal tissue at the exact location where it is detected
• Enables physicians to identify where to biopsy rather than perform physical biopsies on a random basis
• Capable of detecting dysplasia at deeper level than other image enhancement technologies

About WavSTAT
The WavSTAT Optical Biopsy System employs a spectrophotometry technique called Laser Induced Fluorescence (LIF) to optically illuminate and analyze tissue using a standard biopsy forceps. The System uses an optical fiber to send cool, safe UV laser light into suspected tissue, where the light reflects back to a computer at different frequencies, depending on the type of tissue. For example, in abnormal tissue, cells fluoresce differently than in healthy tissue and have a different “signature” that our system can interpret as either normal or abnormal. This can greatly assist the physician by providing an additional indication, displaying a green light for normal tissue and a red light for abnormal tissue. If the tissue appears abnormal, physicians can also use the WavSTAT System to biopsy the tissue.

The WavSTAT has FDA clearance to market for detecting pre-cancerous and cancerous tissue in the colon. The Company made several upgrades to its original technology before introducing it at this year’s DDW and launching it in the European market. SpectraScience is planning a full-scale market launch in the US in late 2010 or early 2011. Currently the Company holds approximately 60 patents for its optical probes and underlying technology.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience’s actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience’s other reports filed with the Securities and Exchange Commission (“SEC”) that attempt to advise interested parties of the risks and factors that may affect SpectraScience’s business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company’s LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

SAN JOSE, CA–(Marketwire – July 27, 2010) –  NightHawk Radiology Services, which provides high-quality, cost-effective services to approximately 1,600 healthcare sites — including 26 percent of all U.S. hospitals — has selected the Cisco (NASDAQ: CSCO) Unified Computing System® as a highly available and scalable platform for the company’s new main data center, which consolidates many smaller server sites around the country into a single primary site. NightHawk Radiology processes 3 million radiology studies per year with an average turnaround time of under 20 minutes per study, uses the flexible architecture of the Cisco Unified Computing System and its virtualized environment to support its goal of providing best in class radiology services and ensuring patients receive timely service 24 hours a day, seven days a week. The Cisco Unified Computing System unites computational, network, storage access, and virtualization resources in a single energy efficient system that reduces IT infrastructure costs and complexity, helps extend capital assets and improves business agility.

In addition to its impact on customer-facing services, deploying the Cisco Unified Computing System and Nexus 5000 data center switches has resulted in lower costs, easier management, and improved business agility for NightHawk Radiology. With the new system, the IT team reduced servers by 50 percent, reduced the time needed to deploy and manage servers by 80 percent, reduced cabling infrastructure by a factor of five, and can provision servers in just 20 minutes..

KEY FACTS / HIGHLIGHTS

• NightHawk provides a complete suite of high-quality, cost-effective solutions, including professional services, and an advanced, proprietary clinical workflow technology, to increase efficiencies and improve the quality of patient care. NightHawk’s team of U.S. board-certified, state-licensed and hospital-privileged physicians provide radiology healthcare services around the clock, and require a mission-critical data center to support timely information delivery.
• NightHawk has configured eight Cisco Unified Computing System blades as VMware ESX servers, each hosting approximately 10 virtual machines, with plans to double the number of virtual machines in the future. NightHawk also uses the Cisco Nexus 1000V Switch, a software switch that operates inside the VMware ESX hypervisor to give the network team complete visibility into the virtual machine environment for easier management.
• NightHawk Radiology has deployed a full suite of Cisco data center solutions. In addition to the Cisco UCS and Nexus 5000 Series data center switches, the company also deployed Cisco Nexus 2000 Series Fabric Extenders, Cisco MDS storage switches, and the Cisco Catalyst® 4900 Series switch as part of the overall infrastructure. These solutions will enable NightHawk to deploy unified fabric in the data center that is more cost-effective, lower in power and cooling demands, and easier to manage.
• Cisco Services and World Wide Technology supported the project with design, planning and deployment to help NightHawk achieve its goal to design a next-generation system that scales easily and provides investment protection. In addition to the Cisco data center technologies, the solution includes a VMware virtual environment and NetApp storage infrastructure. 
• The Cisco Unified Computing System enables NightHawk to achieve:
  • Competitive Differentiation through High Availability: The Cisco Unified Computing System delivers the high availability that is crucial in an industry where server outages not only cause revenue loss, but also delay delivery of critical patient care. The ease of moving virtual machines between servers helps ensure adequate compute capacity between midnight and 5:00 a.m., when the company receives three-quarters of its images. Server operating system upgrades can be quickly achieved by moving virtual machines to a different blade, and moving them back after. With UCS, Nighthawk no longer has to postpone software updates out of concern for reduced production capacity.
  • Simplified Management: Using the Cisco Unified Computing System Manager service profiles, an administrator can change an operating system configuration and then apply it to multiple server blades at the same time, saving time and reducing configuration errors. Firmware upgrades are easier as well, because the IT team simply attaches the upgrade to the template, and then Cisco UCS Manager automatically updates all server blades associated with that template. This means the IT team can update all servers in just 30 minutes compared to the 20 hours required previously.
  • Lower Costs: NightHawk has made significant cost savings through the need to maintain fewer physical servers as well as halving the number of cables and network interfaces needed to support virtualization. This means more of NightHawk’s power and cooling budgets can be used on servers. 
  • Increased Business Agility: The Cisco Unified Computing System Manager has decreased the time needed to deploy and manage servers by 80 percent, while also increasing stability and availability.

SUPPORTING QUOTES

“Systems availability is a paramount concern in our industry as server outages, even brief ones, can prohibit the delivery of patient care. Because medical practitioners and patients depend on our systems to be 100 percent reliable, we looked for technology with the highest level of redundancy and resiliency. With the Cisco Unified Computing System and Nexus solutions, we’ve experienced extremely high availability, coupled with lower costs and simplified management. Cisco UCS delivers the high availability we need to attract and retain customers.”

-Ken Brande, Vice President, IT, NightHawk Radiology Services

SUPPORTING RESOURCES

• View Cisco Unified Computing website
• Read Cisco Data Center Networks blog
• View Cisco Services
• Read NightHawk Radiology Case Study

Technorati Tags: Cisco, Data Center, Data Center Switches, Unified Computing System, Storage

About Cisco Systems
Cisco (NASDAQ: CSCO), the worldwide leader in networking that transforms how people connect, communicate and collaborate, this year celebrates 25 years of technology innovation, operational excellence and corporate social responsibility. Information about Cisco can be found at http://www.cisco.com. For ongoing news, please go to http://newsroom.cisco.com.

Cisco, the Cisco logo, Cisco Systems, Cisco Unified Computing System and Catalyst are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

For direct RSS Feeds of all Cisco news, please visit “News@Cisco” at the following link:

http://newsroom.cisco.com/dlls/rss.html

Click here to see all recent news from this company

TAMARAC, FL–(Marketwire – July 27, 2010) –  AcuMedSpa Holdings, Inc. (PINKSHEETS: AMSZ), a provider of Medical Aesthetic, Spa and Acupuncture services, announced it is initiating a share buyback program in order to lower the outstanding share count and increase shareholder value.

The company’s board of directors is reviewing and wants to purchase shares of AcuMedSpa on the open market and would like to retire those shares back into the treasury. The goal of the program is to purchase up to 10 million shares which will be retired immediately in order to reduce the outstanding shares by the total amount of shares purchased. The current outstanding share total is 146,610,679.

In recent months the company has taken important steps to improve shareholder value by reforming the share structure. Both the outstanding and the authorized shares have been reduced, and decision making power has been given to shareholders over all major decisions including all future share structure changes.

AcuMedSpa Holdings President Gregory Antoine, stated, “This share buyback program is the latest in a series of actions we have taken in our ongoing effort to improve shareholder value. Many small company investors have grown accustomed to share dilution, but we are in effect doing the opposite of dilution by eventually reducing the outstanding shares.” Mr. Antoine continued, “Reduced outstanding shares will benefit the shareholders in several ways and improves the company’s financials. Calculating our earnings with a lower outstanding share total will increase our earnings per share and reflect better on the balance sheet.”

Please follow our progress on twitter: http://twitter.com/acumedinc

For additional info please visit our website: http://www.acumedspa.com/

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements as a result of various factors, and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and AcuMedSpa Holdings, Inc. takes no obligation to update such statements.

KANKAKEE, IL–(Marketwire – July 27, 2010) –  Riverside Medical Center, a south Chicago, Illinois hospital network, is expanding its role as a teaching hospital with the creation of a residency program in Internal Medicine. Riverside also offers fellowships in Gastroenterology and Cardiology. In its inaugural year of the three-year program, the team of residents and various faculty members will work side by side treating patients at various Riverside, Illinois hospital facilities.

“Becoming a teaching hospital really elevates the level of care for the patient and the community,” said Dr. Naresh Chandan, DO, FACOI, FACP, Riverside Medical Center Director of Medical Education and Internal Medicine Program Director. “Not only does it give patients another set of eyes looking out for them, it continues to instill confidence in their care at Riverside. To teach is to learn twice.”

“A residency program at any hospital or clinic is a stage of graduate medical training where physicians, who have received their medical degree, practice under the close supervision of fully licensed physicians. Successful completion of residency training is a requirement to practice medicine independently,” Chandan continues.

Riverside’s Internal Medicine Program provides a holistic learning environment. “The program prepares residents to practice independently in general osteopathic Internal Medicine or to enter into a sub-specialty fellowship program,” said Dr. John Jurica, Riverside Medical Center vice-president of medical affairs.

In addition to an Internal Medicine residency program, Riverside also offers a sub-specialty fellowship in Cardiology and Gastroenterology. The three-year Cardiology fellowship program offers one position per year. The Cardiology Fellowship program will provide exposure to a comprehensive treatment plan, including triple bypass and other related heart center services, and will allow the graduate to practice Cardiology anywhere. The overall goal of the Gastroenterology fellowship program at Riverside is to provide the fellow with a well-balanced experience that is essential for a successful community practice.

“Riverside’s residency program is an investment in our community,” Jurica said. “When the time comes for us to be the patients, we can rest assured knowing that we are receiving the best possible care because of Riverside’s unending commitment to teaching and molding residents into world-class doctors.”

To view more on Riverside Medical Center’s world-class residency program, please visit www.RiversideMC.net/residency.

Click here to see all recent news from this company

BRENTWOOD, MO–(Marketwire – July 26, 2010) –  Scrubs & Beyond, a leading retailer of print and solid scrub tops, jackets, pants, lab coats, shoes and accessories, revealed its fall catalog this week. The highly anticipated fall catalog is set to reach customers across the United States during the week of July 25, 2010 and will offer customers old favorites in addition to new items in a variety of colors, styles and price points. 

Scrubs & Beyond is very excited to be introducing their exclusive S&B solids, starting at just $9.99 each, and S&B print scrubs, starting at $14.99 each. There has never been a better time to stock up for fall. These scrubs are made from soft cotton poplin in both unisex and women’s sizing. Extra details in construction for just the right fit every time, it’s easy for busy medical professionals to mix and match favorite fall colors.

This fall animal print scrubs are one of many must-have items. Customers will find a veritable color safari with fun animal prints from Baby Phat, Cherokee, Los Angeles Rose, Cherokee Flexibles, and Koi. Animal-print seeking fashionistas can also take a walk on the wild side in some great styles in animal-print footwear from Alegria, Nurse Mates and Dansko. Customers will see new offerings from favorite brands such as Koi, Landau, Cherokee, Peaches, Barco, Skechers, Urbane, Scrub Zone, Do No Harm and more. 

Customers have been heard and the call to “Just Give it to Me in Black & White” is here for fall in full force. Scrubs & Beyond’s exclusive black and white scrubs will be a favorite for even the most discriminating Scrubinistas. Koi continues to provide outstanding assortments of styles and prints to mix and match with their essential solid basics and has some great offerings in black and white too! 

As the cooler weather leads into fall, Scrubs & Beyond is ready with value-priced holiday prints to get you in the mood for the season. With so many fashion forward scrubs available for fall, now is the perfect time for medical professionals to shop with Scrubs & Beyond and get exclusive looks that can’t be found anywhere else.

To request the Fall 2010 catalog, or to find a list of all Scrubs & Beyond store locations visit www.ScrubsAndBeyond.com, or call direct at 1-888-255-2668. 

Click here to see all recent news from this company

NEW YORK, NY–(Marketwire – July 26, 2010) –  Every two years, healthcare market research firm Kalorama Information releases the highly anticipated update to its industry leading report, “Worldwide Market for In Vitro Diagnostic Tests, 7th Edition.” In seven best-selling editions, Kalorama Information’s lead diagnostic analyst Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing, in one complete volume.

“We’re very pleased to release this completely updated edition of our best-selling title,” said Bruce Carlson, publisher of Kalorama Information. “The idea behind our unique report is that the entire market can be captured in one volume and business planners can use it as a key reference.”

This go-to reference for the IVD industry reveals the trends that are impacting the field now, and provides a realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. All of the major segments of clinical lab testing are covered.

Kalorama has reorganized the presentation of the IVD market in this latest edition in a manner that better reflects how the industry has evolved. For instance, there is an increased focus on lab automation. Due to a lack of trained lab technologists to run the more complex new set of molecular and histological tests and immunoassays, a proliferation of test and lab automation tools has been launched that remove precious human resources from mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones.

“Worldwide Market for In Vitro Diagnostic Tests, 7th Edition” stands as a testament to the Kalorama methodology — real industry knowledge combined with numerous interviews of leading experts in the field and company executives, as well as an exhaustive review of the medical, business, and company literature. More than 900 pages and over 230 key company profiles reveal one vital piece of exclusive industry information after another. The report is available at: http://www.kaloramainformation.com/redirect.asp?progid=79375&productid=2613362.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

MILWAUKEE, WISCONSIN–(Marketwire – July 26, 2010) – Extendicare Health Services, Inc. announced today that 27 of its health centers are the proud recipients of the American Health Care Association and the National Center for Assisted Living’s (AHCA/NCAL) Bronze – Commitment to Quality, National Quality Award in recognition of their strong commitment to continuous quality improvement.

The health centers receiving the award are:

“The AHCA/NCAL Quality Awards – comprised of three levels, Bronze – Commitment to Quality award; a more rigorous Silver – Achievement in Quality award; and a comprehensive Gold – Excellence in Quality award – are the most prestigious recognition of quality within the long term care profession,” stated AHCA/NCAL President and CEO, Bruce Yarwood. This Bronze – Commitment to Quality award recognizes dedicated frontline caregivers, administrators, nurses and physicians, who demonstrate their commitment to quality of care in order to meet the needs for our nation’s most vulnerable population.

As a Bronze award recipient, these health centers demonstrated their organization-wide commitment to a customer-focused facility mission, defined its principal customers and their expectations, and indicated ways that they are striving to meet their needs.

“The Quality Award program is an independently judged, criteria-based, award program. This year, only 456 long term care centers nationwide received this noteworthy award and we are pleased to be counted among them. We are proud of this accomplishment and thank our team members for their strong commitment to excellence,” said Tim Lukenda, Chairman and CEO of Extendicare Health Services, Inc.

AHCA/NCAL’s Quality Award is modeled after the criteria of the Malcolm Baldrige National Quality Award, the nation’s premier award recognizing distinguished achievements. AHCA/NCAL’s award is designed to support both continuous quality improvement efforts in long term care by promoting quality awareness and education and to recognize quality achievements.

About Extendicare

Extendicare Health Services, Inc. located in Milwaukee, Wisconsin is a wholly owned subsidiary of Extendicare Real Estate Investment Trust, or Extendicare REIT (TSX symbol “EXE.UN”). Extendicare REIT is a leading North American provider of long-term and short-term senior care services through its network of owned and operated health care centers. We employ 37,700 qualified and experienced individuals dedicated to helping people live better through a commitment to quality service that includes post-acute care, rehabilitative therapies and home health care services. Our 258 senior care centers in North America have capacity for approximately 28,900 residents. 

OAKLAND, CA–(Marketwire – July 26, 2010) –  The Center for Technology and Aging (CTA), is collaborating with the Administration on Aging (AoA) and the Centers for Medicare & Medicaid Services (CMS) on funding innovative care transition projects for older adults and persons with disabilities through the national system of Aging and Disability Resource Centers (ADRC).

CTA’s “Technologies for Improving Post-Acute Care Transitions,” (Tech4Impact) grants are designed to encourage ADRC programs (www.aoa.gov/AoARoot/Grants/Funding/index.aspx) to expand use of technologies that promote better patient transitions from hospitals, rehabilitation centers or nursing facilities back to homes or other community settings.

According to The New England Journal of Medicine, avoidable hospital readmissions within 30 days of discharge cost Medicare $17.4 billion annually.

“We are privileged to be a partner in this national effort to improve care transitions,” said David Lindeman, director of the Center for Technology and Aging. “Improving care transitions and lowering hospital readmissions is a national priority. Use of selected technologies, such as remote patient monitoring and medication management technologies, is associated with reduced hospitalizations, so it makes sense to focus on expanding their use.”

Tech4Impact grants will complement grantee funding made available through the $60 million AoA and CMS initiative, “Implementing the Affordable Care Act: Making it Easier for Individuals to Navigate their Health and Long-Term Care through Person-Centered Systems of Information, Counseling and Access.” Complete details are available at: www.aoa.gov/AoARoot/Grants/Funding/index.aspx.

CTA will make Tech4Impact funds available to states that are awarded grants by AoA/CMS for program Option D: ADRCs Evidence-Based Care Transition Programs. (AoA/CMS grant applications are submitted electronically at www.grants.gov.) The CTA application for states will be released by September 30, 2010, and full proposals will be due October 15, 2010. Grants are expected to commence by January 2011. Additional guidelines pertaining to the Tech4Impact grants are available at www.techandaging.org 

ADRCs (www.adrc-tae.org) are community-based programs designed to streamline access to long-term care services under the auspice of the Administration on Aging, an arm of the U.S. Department of Health and Human Services.

In addition to the Tech4Impact grants, CTA administers grant-funding programs for projects that seek to expand the use of medication optimization and remote patient monitoring technologies for the care of older Americans.

The Center for Technology and Aging (www.techandaging.org) supports the rapid adoption and diffusion of technologies that enhance independence and improve home and community-based care for older adults. Through grants, research, public policy involvement and development of practical tools and best practice guidelines, the Center serves as an independent, non-profit resource for improving the quality and cost-effectiveness of long-term care services. The Center was established with funding from The SCAN Foundation (www.thescanfoundation.org) and is affiliated with the Public Health Institute (www.phi.org) in Oakland, CA.

Click here to see all recent news from this company

ROCKVILLE, MD–(Marketwire – July 26, 2010) –  MarketResearch.com has announced the addition of Business Insights’ new report “Drug Discovery Collaborations between Academia and the Pharmaceutical Industry: Cultural factors, intellectual property considerations, case studies, and future trends,” to their collection of Pharmaceuticals market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

The pharmaceutical and biopharmaceutical industries are engaged in a business environment which is witnessing a dramatic escalation of R&D costs, key patent expiries, and sustained high attrition rates for new molecules in development.

In response, pharmaceutical companies have recognized the need to expand the range of creative stimuli for their research processes in order to reinvigorate their drug discovery pipelines. Consequently the industry has sought to develop external collaborations not only with other companies but also more frequently with academia, to obtain access to new technologies to enhance their drug discovery capabilities and to in-license candidates for further development. Indeed, collaboration is becoming an essential component of today’s drug discovery efforts and it is commonly undertaken with multiple partners through an often iterative, continuous, and long lasting process, which adds to the complexity of efficiently managing both the collaboration itself and the data generated.

This report explores the opportunities and challenges that are presented by collaboration with university researchers as well as identifying the key inputs from both the industrial and academic partners. The different organizational cultures and structures are examined along with consideration of the goals for each institution and the issues these create. The report discusses the various types of agreement which can be used, highlights legislation of importance to the appropriate protection of intellectual property, and presents case studies of notable collaborations In addition the report offers thoughts on the future for collaborative agreements and the benefits they will bring to both parties.

Questions Answered within the report include…

• What are the key drivers influencing change to a more collaborative approach to R&D in the pharmaceutical industry?
• What are the latest developments in the collaborative approach to R&D and which models represent the best opportunities for the pharmaceutical industry?
• What are the issues and concerns over the evolving collaborative R&D paradigms?
• What are the intellectual property management issues that should be considered by each party?
• Which changes in patent legislation are of greatest relevance to the formation of collaborations in different countries?
• What are the different types of academia-industry collaborations?
• What are the pros and cons for each party in academia-industry collaborations?
• What are the critical success factors for academia-industry collaborations?
• What are the main factors to take into account when negotiating academia-industry collaborations?
• What are the cultural, change management and goal alignment challenges?
• What are the future directions for academia-industry collaborations?

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=2738133.

Click here to see all recent news from this company

CHICAGO, IL–(Marketwire – July 26, 2010) –  Typenex Medical, LLC, a leader in transfusion recipient verification solutions, has launched their latest barcoded blood band innovation, the FlexiBlood Recipient Verification System.

The FlexiBlood Recipient Verification System was developed using feedback from blood bankers and nurses to ensure that the product improved on the legacy “band and form” recipient verification systems available today. FlexiBlood uses GS1-128 linear barcodes and can accommodate pre-printed patient information labels to reduce transcription errors at the bedside and in the blood bank. It also boasts a barcoded specimen tube sticker that stays attached to the band during application to help promote the accurate labeling of the pre-transfusion specimen at the patient bedside.

“Blood bankers asked for a solution that leverages barcodes to reduce transcription errors and provides a way to help clinical staff label specimens accurately to avoid wrong blood in tube errors,” said Scott Leece, General Manager of Typenex Medical. “Nurses wanted a solution that is easy to use, comfortable for patients, and that supports them throughout the specimen collection and blood administration processes. FlexiBlood was designed to meet all of these requirements.” 

FlexiBlood has additional features that differentiate it from other offerings, such as the ability to be easily reapplied if removed during the patient stay using the Typenex R3 Attachment System and directions for use on every FlexiBlood form. “Based on clinical feedback and the many features of FlexiBlood, we are confident that it is a better solution than Ident-A™ Blood or Securlink®,” stated Leece.

The FlexiBlood Recipient Verification System has two standard forms and six standard insert band colors. For more information on FlexiBlood, please call (866) TYPENEX or visit http://www.typenex.com/. 

About Typenex Medical
Typenex Medical enables hospitals to achieve safer transfusion practices via our suite of recipient verification solutions. These solutions — our Original Alphanumeric Bands, our Next Generation Barcode Bands, and our FlexiBlood Recipient Verification System–provide independent, unique identifiers in various embodiments to help hospitals provide control over their transfusion processes and reduce the costly and dangerous errors associated with blood transfusions. Typenex also improves safety in the laboratory via our TypeSafe™ Segment Sampling Device, which is used to safely pierce blood segments for cross-matching.

Ident-A™ and Securlink® are trademarks of Precision Dynamics Corporation.

MONMOUTH JUNCTION, NJ–(Marketwire – July 26, 2010) –  CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that it is exhibiting at two leading military healthcare conferences in August. The first is the 13^th Annual Force Health Protection Conference (FHP) at the Phoenix Convention Center in Phoenix, Arizona, where CytoSorbents will exhibit in Booth #507 from August 10-11, 2010 (http://phc.amedd.army.mil/fhpc/). The FHP conference is expected to gather more than 2,000 healthcare medical providers, policymakers and vendors from around the world, focused on the latest research, services and products for disease prevention and treatment, safety and homeland security for both military and public health purposes.

The second is the Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference to be held at the Tradewinds Beach Resort, in St. Pete Beach, Florida. CytoSorbents will be exhibiting from August 16-19, 2010 in Booth #19. ATACCC is the Department of Defenses’ premier scientific meeting that addresses critical advances in trauma medicine and the unique medical needs of the warfighter (https://www.ataccc.org/). At both venues, the Company will be showcasing its blood purification technology with a hands-on demonstration of how the device works, how it is easily administered, and how it could be applied in a number of clinical situations facing critically wounded military personnel.

Dr. Phillip Chan, Chief Executive Officer and President, commented, “Members of our military forces put their lives on the line every day, not only in Iraq and Afghanistan, but all over the world. The injuries they sustain in protecting our freedom include penetrating wound injuries, infection and sepsis, and blast, trauma, crush and burn injuries that are extremely complex and severe. Standard of care therapy remains predominantly supportive, and does not address the cytokine storm and subsequent severe inflammation that can lead to multi-organ failure and death in these patients.” 

Dr. Chan continued, “We believe that our flagship product CytoSorb™, a powerful cytokine removal technology currently in human clinical trials, is the key to changing the current treatment paradigm of ‘supportive care and watchful waiting’ to one of ‘active treatment,’ potentially saving more lives. In addition, blood purification using CytoSorb or other resins under development, may solve many other vexing problems facing the military and the DOD, such as how to treat soldiers or civilians exposed to chemical or biologic warfare. Exhibiting at these major conferences continues our efforts to build funding support for our technologies within the military and the DOD and to expand the number of clinical applications for our products.”

About CytoSorbents and CytoSorb™

CytoSorbents Corporation is a critical care focused therapeutic device company in clinical trials to treat severe sepsis, the end result of “overwhelming infection,” with a novel blood purification device called CytoSorb™. Severe sepsis afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Severe sepsis is typically triggered by bacterial infections like pneumonia, or viral infections like influenza. However, it is the body’s abnormal immune response to the trigger that leads to severe inflammation and the unregulated, massive production of cytokines, often called “cytokine storm,” that then causes multi-organ failure and often death. CytoSorb™ is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial – a multi-center, randomized, controlled clinical trial using CytoSorb™ to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb™ in the European Union and then commence clinical trials in the U.S. for approval. Importantly, cytokine reduction via CytoSorb™ has broad applicability to a number of other critical care diseases where cytokine storm plays a detrimental role, including burn and smoke inhalation injury, trauma, acute respiratory distress syndrome, advanced influenza, acute pancreatitis and others. CytoSorb™ is one of a number of different resins designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy during treatment of cancer with high dose regional chemotherapy, drug detoxification and others. Additional information is available for download on the Company’s website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management’s current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company’s medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company’s products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company’s Form 10-K filed with the SEC on April 9, 2010, which is available at http://www.sec.gov.

ROCKVILLE, MD and SEOUL, SOUTH KOREA–(Marketwire – July 26, 2010) –  Seegene today announced SeePrep™ and SeeCycler™, new clinical instrumentation optimized for Seegene’s multiplex real-time detection tests. SeePrep performs automated magnetic bead nucleic acid extraction, and SeeCycler is an automated detection system for processing samples in real-time. With the addition of these equipment Seegene is now able to provide a complete molecular diagnostic workflow optimized for its multiplex tests, including nucleic acid extraction, amplification, real-time PCR testing and data analysis. The complete system will be on display at the 2010 Annual Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), booth #1800.

“Seegene multiplex real-time PCR products are defining a new era of powerful assays that can rapidly and accurately diagnose a pathogenic infection and genetic mutation. These tests arm medical professionals with the information they need for better and more cost-effective patient care,” said Jong-Yoon Chun, Chief Executive Officer of Seegene. “SeePrep and SeeCycler are the cutting edge in test sample prep and processing, and are a perfect complement to our multiplex testing format. Used together as a complete system, clinicians will benefit from a comprehensive system which simplifies and speeds up the entire test process.”

Seegene is pioneering a new category of multiplex PCR technology that enables the simultaneous detection of viruses and bacteria in a single reaction. Seegene currently has a wide range of assay panels for multiple pathogen screening. The assays primarily target viral and bacterial infections and include panels for viral respiratory infections, sexually transmitted diseases, herpes, diarrhea, HPV, viral meningitis and sepsis.

SeePrep is an automated nucleic acid extraction machine utilizing magnetic bead technology. The hallmark of the instrument is the ability to utilize specimens that are very difficult to extract by any other instrument.

SeeCycler uses patented block dissipation technology for accurate and fast heating and cooling rates, required for better efficiency in DNA amplification, resulting in fast reaction time. It has a capacity of 96 wells and covers and with 6 channels, 5 different analyses can be detected in one sample.

About Seegene

Seegene, Inc. is the leading biotechnology company developing, manufacturing and marketing innovative molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ™, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex® and Magicplex® system which are Real-time PCR detection platform adapting DPO™ and READ™ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.

ATLANTA, GA–(Marketwire – July 26, 2010) –  ALR Technologies Inc. (OTCBB: ALRT) announces that on July 23, 2010 the Company submitted a 510(k) application to the FDA for its proprietary Health-e-Connect (HeC) System. The HeC system is an internet-based product intended for diabetic patients and their health care providers to improve communication and monitoring of patients’ health management programs. One aspect of the system is that HeC will incorporate data uploaded from patients’ glucometers into the ALRT database to quickly assess user compliance and performance compared to provider set targets. The HeC system currently supports data transfer from glucometers manufactured by Abbott, Bayer, Lifescan (a Johnson & Johnson company) and Roche.

In a recently presented clinical evaluation, diabetic patients using the HeC system showed statistically significant improvement in A1c when compared to a control group using standard methods for monitoring and feedback.

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com. 

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate,” “expect,” “anticipate,” “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.

MENOMONEE FALLS, WI–(Marketwire – July 23, 2010) –  Assisted Living Concepts, Inc. (NYSE: ALC) announced that it plans to release its 2010 second quarter financial results after the New York Stock Exchange closes on Monday August 9, 2010. The release will be posted on ALC’s website at www.alcco.com. ALC has scheduled a conference call on Tuesday August 10, 2010 at 10:00 a.m. (ET) to discuss its financial results for the second quarter. The toll-free number for the live call is (800) 230-1096 or international (612) 332-0107. A taped rebroadcast of the conference call will be available approximately three hours following the live call until midnight on September 10, 2010, by dialing toll free (800) 475-6701 or international (320) 365-3844 and using access code 165684.

About Us

Assisted Living Concepts, Inc. and its subsidiaries operate 211 senior living residences with capacity for approximately 9,400 residents in 20 states in the United States. ALC’s residences typically consist of 35 to 60 units and offer residents a supportive, home-like setting and assistance with activities of daily living. ALC employs approximately 4,100 people.

LANHAM, MD–(Marketwire – July 23, 2010) –  The Residence at Greenbelt, offering the new standard in modern assisted living, announced today that it will celebrate its grand opening on Tuesday, July 27^th and Wednesday, July 28^th, 2010 from 4pm-7pm. During this monumental two-day event, guests can experience a VIP tour of The Residence on Greenbelt, its new modern models and see first-hand the dignity and vitality of assisted living in a unique community geared towards residents, their families and friends. 

A special tree-planting dedication ceremony will take place on the second day, Wednesday, July 28^th. Samuel H. Dean, Councilman for Ward 6 in Prince George’s County, will lead the dedication of a Southern Magnolia tree that was graciously donated by Behnke Nurseries. Additionally, summer fare and jazz entertainment will be provided both days.

At The Residence on Greenbelt, the warmth and comfort of home and modern convenience come together to define modern assisted living. This unique community offers charm, extensive care and superior care, while allowing residents to experience its modern set of amenities including a Skype lounge and stately movie theatre equipped for the hearing impaired. Conveniently located on Greenbelt Road, The Residence on Greenbelt has recently undergone a complete renovation that has created a vibrant and interesting senior living residence, where residents can experience unrivaled service in modern and fun surroundings.

Three different service programs exist at The Residence on Greenbelt, providing the right match for the needs of seniors. In addition to Assisted Living, the community offers a Special Needs living area that provides for residents with higher acuity and mobility needs in an environment with features focused on maximizing independence while offering comfort and service. The Residence on Greenbelt also provides the Pathways Memory Care Program, an exceptional option for seniors with memory impairments as it offers a stimulating and engaging environment for residents and peace of mind for their families and friends.

For more information about The Residence on Greenbelt, or to attend the Grand Opening event, please call (866) 712-1172 or visit TheResidenceonGreenbelt.com.

About IntegraCare
IntegraCare’s mission is to “improve the quality of life for its employees, residents, and their families.” The company’s goal is to create an environment where its primary customer, the employee, experiences respect, dignity, and personal development. By providing this environment for its employees, the second half of our mission, “improve the quality life for our residents and their families,” will be achieved.

INDIANAPOLIS, IN–(Marketwire – July 23, 2010) –  Health Systems International (HSI), a global provider of outsourced medical cost management solutions, has just received the spotlight in the Indianapolis Business Journal’s Fastest Growing Indianapolis-Area Private Companies — coming in at number 3. View the article at http://www.us-hsi.com/files/Fastest%20Growing%20HSI_July%202010.pdf. This is the second year in a row HSI has received this honor. In 2009, the company appeared on the list at number 9. 

Russell W. Sherlock, Chief Executive Officer of HSI, said, “Our strong sales team and our service results help us to continue to grow even in tough economic times. Healthcare continues to get more complex, and HSI works consultatively with clients to find out how each one can carve dollars out of the healthcare bill. Everyone’s program is unique, and we offer niche services and solutions to fit many markets.”

HSI solutions include cost containment technology and business services customized to meet specific industry needs in the PPO, Maritime, Workers’ Compensation, Property and Casualty, HMO, Health Insurance Carrier, TPA, Self-funded, Reinsurer, and International Health Payor Markets.

About HSI
Headquartered in Indianapolis, Indiana, HSI is a leading provider of outsourced medical cost management solutions. HSI is backed by Great Point Partners, LLC, a private investment firm with over $900 million of equity capital under management. Since 1987, HSI has utilized proprietary technology, experienced staff medical discount services to relieve clients’ administrative burdens and achieve the lowest possible cost of medical care. Visit www.us-hsi.com for more information.

NEW YORK, NY–(Marketwire – July 23, 2010) –  (PINKSHEETS: SREH) — SREH Scientific News International (www.scientificnewsroom.com) releases its subscription-based gross revenue projections today as it prepares for an upcoming wave of fall medical conferences for its industry reporting brainchild, www.scientificnewsroom.com.

The projections have been laid out conservatively and factors in a variable attrition rate. “Further,” states CEO Anthony Dibiase, “these figures were calculated with an assumption that only the lower subscription tier was selected by all members. We did this to remain conservative in our projections and even a fraction of doctors choosing to subscribe as premium members would have a significant impact on these numbers. As well, these figures are only based on subscription fees and do not include iPhone app sales, doctor2doctor social networking platform upgrades or doctor2doctor prospective ad revenue.”

SNI Execs are confident it can reach at least 10% of its target market by July 31, 2011 resulting in more than $1 million in gross revenues there. SNI target market includes professionals from all of the major fields the site currently covers: Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology, Urology and Radiology. By year 3, the site expects to reach approximately $5 million in subscription fees alone. “With supplementary medical fields, increased conference attendance, additional iPhone apps and doctor2doctor revenues, we release these projections with the understanding that they are only a fraction of revenues overall for the company. Expanded projections will be released in the near future to reflect additional revenue streams,” comments Dibiase.

CUTTING EDGE MEDICAL MEETING NEWS EXCLUSIVELY AT Scientific News International! (www.scientificnewsroom.com) is SREH’s premiere all-in-one platform for medical conference and news information focusing on Cardiology, Gastroenterology, Hematology, Nephrology, Oncology, Primary Care, Rheumatology and Urology. The site is the web’s only online resource for medical professionals with access to the latest, cutting edge data presented at major medical meetings worldwide. Staffed by global medical writers, SNI reports the most current research and therapy findings directly. The site’s profitability is IP and subscription based without bias from any medical or pharmaceutical provider. 

In the beginning, there was… Fishing, Manga, global tide reports and more! Get your iPhoneMobile2Earth (www.mobile2earth.com) app now. Choose from the iPhone King James Bible, fishing reports worldwide, Japanese e-books and comics and so much more! Get ready, as Mobile2Earth unleashes phase 1 of its iPhone app releases for mass consumption.

Safe Harbor: This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

ALEXANDRIA, VA–(Marketwire – July 23, 2010) –  The American Diabetes Association applauds the new White House rule which will help people with diabetes and other chronic diseases appeal the denials of health insurance claims. This rule comes under the new Patient Protection and Affordable Care Act. The rules will help simplify the denial process and create consistency in all 50 states.

“In order to stay healthy, people with diabetes have to manage their disease with supplies like test strips, meters and insulin,” said Nash Childs, PE, Chair of the Board, American Diabetes Association. “Diabetes is a costly disease and without good coverage, the costs can make it difficult to manage properly. It is important that people with diabetes are treated fairly and given the opportunity to appeal any claims that are denied. The American Diabetes Association is grateful to the Obama administration for recognizing the need to make this available to everyone.”

The American Diabetes Association is leading the fight to stop diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit www.diabetes.org. Information from both these sources is available in English and Spanish.

id=”nav_links”>

WEST PALM BEACH, FL–(Marketwire – July 22, 2010) – HearUSA, Inc. (NYSE Amex: EAR), a leader among the nation’s hearing care providers, will hold a conference call on Tuesday, August 10, 2010 to discuss results for the second quarter ended June 26, 2010. Financial results will be issued in a press release after the close of the market on the same day.

HearUSA’s Chairman and CEO Stephen J. Hansbrough, President and COO Gino Chouinard, and CFO Frank Puñal will host the call starting at 4:30 p.m. Eastern time. A question and answer session will follow management’s presentation.

To participate in the call, dial the appropriate number 5-10 minutes prior to the start time, request the HearUSA conference call and provide the conference ID: 7HEARUSA.

A Web audio simulcast and replay will be available via the investor relations section of the company’s website at www.hearusa.com.

If you have any difficulty connecting with the conference call or webcast, please contact Liolios Group at 1-949-574-3860.

A telephone replay of the call will be available later that evening and will be accessible until August 17, 2010:

About HearUSA
HearUSA is the recognized leader in hearing care for the nation’s top managed care organizations through its 177 company-owned centers and network of more than 2,000 hearing care providers. HearUSA is the nation’s only hearing care provider accredited by URAC, an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation. HearUSA is also the administrator of the AARP Hearing Care program, designed to help millions of Americans aged 50+ who have untreated hearing loss. For more information about HearUSA visit www.hearusa.com, or go to www.hearingshop.com for a wide selection of hearing related products available for purchase online.

BELGRADE, SERBIA–(Marketwire – July 22, 2010) – Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) http://www.htdsmedical.com) is pleased to announce that researchers from its Slavica BioChem (www.slavicabiochem.com) division established the cooperation with world-leading market analysis company from UK.

Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said, “The Datamonitor Group (http://www.datamonitor.com/) is world leader in the business intelligence sector. We expect that the multiple sclerosis and traumatic brain injury pipeline and unmet analysis needs of these two markets, prepared by Datamonitor’s healthcare and pharmaceutical analysis team, will provide us with insight into most recent findings in order to be a step ahead to our competitors. After getting permission, complete material comprising of clinical opinion, leader intelligence, best-in-class case studies, R&D pipeline, unmet need analysis, scenario-based revenue, epidemiology forecasting, a slide pack and a data pack covering seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) will be available at the HTDS (http://www.htdsmedical.com) and Slavica BioChem (www.slavicabiochem.com) web sites.

About Mina Mar Group:

Mina Mar Group (MMG) is a corporate consultancy firm that specializes in small cap or OTC market business services, including public markets in Frankfurt, Germany, and the UK. We provide our clients with comprehensive advisory and consulting services regarding mergers and acquisitions, including reverse mergers of private companies into publicly traded entities, and special purpose companies (SPC) offshore. MMG also offers a full suite of related ancillary services subsequent to the successful completion of a reverse merger, including private placements, Pink Sheets Adequate Disclosure documentation, various SEC regulatory filings and a broad range of other corporate governance matters. Mina Mar Marketing Group, MMMG (www.minamargroup.net), offers publicly traded companies full array of services such as Investor Relations and maintenance investor awareness. Mina Mar Group pioneered the “Go Public Free” program, the first firm to challenge the short sellers, stock bashers and repeal of the “Communication Decency Act”. Visit www.minamargroup.com/ice to learn more.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company’s email database for press releases, “Friday Tips” industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe for opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

ALEXANDRIA, VA–(Marketwire – July 22, 2010) – Darius Gilbert, CEO of Dynamic Solutions, a strength training company, announced that his speed and performance training programs will incorporate the proprietary Movement Training Systems (MTS) Body Position evaluation and performance improvement processes.

As summer training camps and clinics kick into high gear to prepare athletes for the fall sports season, athletes of all ages are looking to increase total body strength and speed in specific sports through strength training. Dynamic Solutions is placing greater emphasis on “movement mechanics.” Movement mechanics are used to teach an athlete how to stabilize position, carry the body in motion, and correctly initiate motion. 

Through its web-based tools, MTS measures flow of muscle reaction from the foot through the entire body which dramatically improves motion, strength, athleticism and speed in young athletes. Through the MTS process, Dynamic Solutions can evaluate the strengths and weaknesses of the individual athlete and structure drills to cue changes for each athlete and increase athletic performance.

“In order to improve speed and performance, we need to measure the initial level of each athlete’s ability,” said Gilbert. “Evaluation becomes our most valuable tool in the process of performance improvement and MTS fills this need.”

“Our goal is to help each athlete be as athletic as possible,” said Vince Stephenson, founder of MTS. “Our system was designed to help athletes, coaches and trainers better understand individual body performance for efficiency.”

Dynamic Solutions and MTS agree that performance is dependent on efficient movement. The best of sport-specific skills are only as good as they can be applied. If an athlete is off-balance, out of position or slow, skills will suffer.

For more information about Dynamic Solutions’ programs, contact: visit www.kettlebellstronginva.com or call 703-209-8696.

For more information about MTS, visit the www.movementtrainingsystems.com or contact [email protected]

id=”nav_links”>

IRVINE, CA–(Marketwire – July 22, 2010) – For marketing, sales and research professionals who need to understand the complex relationship of physician-to-hospital affiliations, SK&A, A Cegedim Company, today announced the release of an enhancement to its Office-Based Physician database that links practicing physicians to hospitals. SK&A has identified 1,143,420 hospital affiliations for the 680,000 physicians in its industry-leading database. Ninety percent of doctors are affiliated with at least one hospital. The average physician is affiliated with 1.7 hospitals.

SK&A enhanced its database of affiliations by surveying more than 235,000 U.S. medical offices over a six-month period to determine the unique connection between physicians and the hospitals within their sphere of practice or specialty. The survey was conducted by SK&A’s Research Center in Irvine, Calif., as part of its daily telephone verification of medical site information.

“Understanding the distinct and multifaceted relationship between physicians and hospitals is absolutely essential to succeed in today’s competitive marketplace,” said Dave Escalante, SK&A’s Vice President of Data and Information Solutions. “SK&A clients, across 12 major U.S. industries, need this important affiliation information to better plan and execute their sales, marketing and market-research programs. High-quality affiliation data enables more effective selling to physicians, supports enhanced targeting and segmentation, and provides more insight into the complex relationships that influence and drive market behaviors,” continued Escalante.

Through this latest delivery, SK&A has expanded its comprehensive, fully telephone-verified database of affiliation information in healthcare. For example, SK&A has identified 320,197 physicians who are affiliated with group practices. Affiliation coverage includes the ability to accurately identify the sites and personnel within:

• Integrated health systems and networks
• Hospital systems and networks, defined by ownership or affiliation
• Group practice networks
• Affiliated nursing homes
• Affiliated healthcare providers, professionals, administrators, executives and office personnel to health systems, hospitals, group practices, and nursing homes.

All of the affiliation information managed by SK&A, including the newly enhanced
physician-to-hospital affiliations and the baseline reference database, is available in Cegedim Dendrite’s OneKey service.

SK&A clients utilize affiliation information to:

• Deliver more accurate online directories of physicians for patient searches
• Understand the influence health systems and hospitals have on their network (e.g. EHR adoption and pharmaceutical sales rep access to physicians in medical offices)
• Enhance coordinated marketing and sales-resource planning and execution
• Accurately define markets and their overall potential.

About SK&A, A Cegedim Company
SK&A is a leading provider of healthcare information solutions and research. SK&A, as part of Cegedim’s global OneKey® offering, researches and maintains contact and profiling information for over two million healthcare practitioners, including 900,000-plus prescribers. SK&A also offers the only 100-percent telephone-verified database of email addresses of U.S. prescribers and professionals working at active healthcare sites. SK&A’s customers include many of America’s most recognized healthcare, life sciences and pharmaceutical companies. Please visit www.skainfo.com for more information or www.skalivecounts.com for counts and ordering. SK&A is part of the France-based Cegedim S.A. Group.

About Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,600 people in more than 80 countries and generated revenue of €874 million in 2009.
Cegedim SA is listed in Paris (EURONEXT: CGM).
To learn more, please visit www.cegedim.com.

Click here to see all recent news from this company

RESTON, VA–(Marketwire – July 22, 2010) –  Santeon Group, Inc. (OTCBB: UBCI) today announced an additional $100,000 contract with the State of Maryland for the latest management process optimization. This represents a continuation of Santeon’s much larger multi-year contract with Maryland for continuous process improvement support through its Business Process Management Suite XIP.

The two new services streamline State operations involved in Healthcare and reduce costs while improving productivity and fraudulent claims:

1. Tracking services provided to patients, verifying specific services are available to patients while also monitoring potential fraud. Also auditors can verify if patients have other insurance that takes seniority for payment of services or if that patient has been previously billed for the service in addition to KDP/BCC. Prior to Santeon’s eCMS process management system, letters were manually typed and mailed to patients, an antiquated solution that was not only costly but time consuming as well.

2. Maryland Health Insurance Plan (MHIP) sends Breast and Cervical a single monthly invoice for paying insurance premiums to selected groups of individuals. The enhanced workflow will determine the types of patients receiving MHIP, and will allow for reviews before and after. In addition, a trail of changes is kept so that BCCDT can provide auditing reports.

Santeon’s CEO Ash Rofail said, “We’re excited to be able to provide cutting edge process management solutions to the State of Maryland. With the successful and timely delivery of this recent enhancement, we expect to leverage significant opportunities for additional revenues from our healthcare division, especially in light of recent federal Healthcare legislation.”

About Santeon Group, Inc.

Santeon Group is a technology company Headquartered in Northern Virginia with offices strategically located in San Diego, Los Angeles, London, Cairo and Dubai. Santeon offers products and services in Healthcare, Energy, Media and Agile Development. Santeon Group provides technically superior end-point process management solutions, streamlining traditional management processes, improving efficiencies and productivity, while reducing the costs of these solutions. For more information please visit the web site at http://www.santeon.com/.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company’s ability to complete a business acquisition. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about UBCI’s future business and financial results, refer to UBCI’s Annual Report on Form 10-K for the year ended December 31, 2009. UBCI undertakes no obligation to update any forward-looking statements that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.

CORAL SPRINGS, FL–(Marketwire – July 22, 2010) –  Willing Holding, Inc. (OTCBB: WHDX) announces that it has completed the acquisition of Accessible Home Health Care.

On July 16, 2010, Willing Holding, Inc. completed the acquisition of the assets of Accessible Home Health Care (www.accessiblehhc.com) from Valiant Healthcare, Inc., a Delaware corporation, through the execution and closing of an Asset Purchase Agreement. Under the reverse merger Valiant (www.valianthealthcare.com) has assumed majority (90%) interest in Willing Holding.

Accessible’s and Valiant’s entire experienced management team has been retained and they continue to run the day to day business of the company.

Accessible’s business model is designed to lead and direct the 21st Century demands of the long term home health care industry by offering a “Complete Home Healthcare Package™” and being a “One Stop Provider™.” Accessible’s primary mission is to provide the highest quality home health care services and products to its patients while adding value to the payers by reducing direct costs and the potential for fraud.

Accessible’s next phase of growth is to expand its company owned units by acquisition of Medicare certified home health care providers in strategic geographic markets.

About Willing Holding, Inc.
Through our Accessible Home Health Care division, we offer and sell a proven one of its kind franchise opportunity to establish and operate a full service medical and personal care Accessible Home Health Care franchise, under our distinctive brand and system. As of July 22, 2010 there are 96 Accessible Home Health Care franchise units and one company-owned unit in 24 states, as well as in India and Kenya.

Forward-Looking Statements
This release is not an offer to purchase or sell securities and may contain statements that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current estimates and projections about Willing Holding, Inc.’s business, which are derived in part on assumptions of its management, and are not guarantees of future performance, as such performance is difficult to predict. The Company assumes no obligation to update information concerning its expectations.

FISHKILL, NY–(Marketwire – July 22, 2010) –  Nano Mask, Inc. (PINKSHEETS: NANM) today announced that it has entered into a manufacturing agreement with a well established Canadian company that will produce Nano Mask’s own proprietarily labeled multi amino acid enzyme cleaning products for the International and United States hospital markets. Nano Mask launched the distribution of this product suite on July 13, 2010 through a network of distributors and manufacturers’ representatives in the United States and internationally.

The Canadian manufacturer has developed a full line of enzyme based and chemical based medical specialty detergents for the demanding cleaning of medical instruments, laboratory glassware, endoscopes and hospital carts. These specialty detergents have become the preferred Multi-Enzyme Based Hospital instrument Pre-Soak and Cleaning Solution in the Canadian hospital market. Nano Mask’s initial products include:

• Nano-Zyme, a Multi Enzyme Based Hospital Instrument Pre-Soak and Cleaning Solution that is a non foaming formulation that does not cause eye, nose, throat, skin or lung irritation as do the current products being used today.

• Nano-Zyme Ortho Plus, a one step pre-soak enzymatic cleaning product specifically designed to emulsify and remove stubborn fats, oils, blood tissue, bone grease and lubricants on Orthopedic and Arthroscopic Instruments.

• Nano-Med Care, a Multi Enzyme Based Pre Clean enzyme gel formulated as a transport gel to initiate the cleaning process at point of use in operating rooms, endoscopy suites, labs and central processing areas.

• Nano-Odor Away, a Clear, Natural and Non Toxic liquid that eliminates odors from colostomy appliances and irrigation units, use of which eliminates the need to use masking agents and caustic chemicals.

“We are excited to launch this line of new green products for the hospital market in the U.S. and internationally,” said Edward J. Suydam, President and CEO, Nano Mask. “The reception from our distributors has been very strong and we expect to broaden our distribution capabilities — especially in international markets — over the coming months.”

Mr. Suydam added, “We entered this venture in an effort to create another source of revenues to complement the orders that we have generated from our distribution of Wein respirators while we continue to work on the completion of our own, proprietary NanoMask™ respirator.”

Separately, the company announced that it was continuing to make progress in bringing its S.E.C. filings up to date.

About Nano Mask, Inc.

http://nanomaskinc.com/

Nano Mask, Inc. is the inventor of the NanoMask, a disposable anti-microbial facemask currently under development and is a distributor of Wein Products’ line of disposable respirators and the new line of hospital detergent products.
Forward-looking Statement

This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. Specifically, any unforeseen delays in distribution may affect the planned timeline for initiating actual sales of the product. NMI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the company could differ significantly from such forward-looking statements.

SOPHIA ANTIPOLIS, FRANCE–(Marketwire – July 22, 2010) – www.nicox.com

NicOx S.A. (NYSE Euronext Paris: COX) today announced the receipt of a
Complete Response Letter from the U.S. Food and Drug Administration (FDA)
related to the New Drug Application (NDA) for naproxcinod. Naproxcinod is
being developed for the relief of the signs and symptoms of osteoarthritis.

The FDA informed NicOx that its review of the NDA is complete and that it
does not approve the naproxcinod application. The FDA has recommended
conducting one or more long-term controlled studies to assess the
cardiovascular and gastrointestinal safety of naproxcinod. Additional
studies to demonstrate a clinically meaningful therapeutic benefit
attributable to the nitric oxide donation were also recommended. No
clinical efficacy studies were requested.

NicOx plans to discuss the Complete Response Letter and potential next
steps as early as possible with the FDA.

The naproxcinod Marketing Authorization Application (MAA) submitted by
NicOx in December 2009 is currently under review by the European Medicines
Agency (EMA).

NicOx remains well funded and had cash, cash equivalents and financial
instruments of ?138.5 million at the end of March 2010. The Company
will publish its financial results for the first half of 2010 on July 30,
2010. NicOx has no long-term debt and is constantly reviewing all aspects
of its cost base to ensure careful conservation of its funds.

NicOx has a broad pipeline of nitric oxide (NO)-donating New Molecular
Entities (NMEs) targeting the therapeutic areas of inflammatory,
cardiometabolic and ophthalmological diseases. NicOx has built a network of
strong partnerships for the development of some of its promising lead
compounds, including alliances with Merck & Co., Inc., Bausch + Lomb and
Ferrer.

Risks factors which are likely to have a material effect on NicOx’s
business are presented in the 4th chapter of the ” Document de
référence, rapport financier annuel et rapport de gestion 2009 ”
filed with the French Autorité des Marchés Financiers (AMF) on
March 5, 2010 and available on NicOx’s website (www.nicox.com) and on the
AMF’s website
(www.amf-france.org).

The Company notably draws the investors’ attention to the following risk
factors:

– Risques liés à la dépendance de la Société
à l’égard du naproxcinod (Risks related to the Company’s
dependence on the success of its lead product naproxcinod)

– Risques commerciaux et développements cliniques (Clinical
developments and commercial risk)

– Risques liés aux contraintes réglementaires et à la
lenteur des procédures d’approbation (Risks linked to regulatory
constraints and slow approval procedures)

– Manque de capacités dans les domaines de la vente et du marketing
(Lack of sales and marketing capabilities)

– Incertitude relative aux prix des médicaments et aux régimes de
remboursement, ainsi qu’en matière de réforme des régimes
d’assurance maladie (Uncertainty on drug pricing and reimbursement policies
and on the reforms of the health insurance systems)

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company
focused on the research, development and future commercialization of drug
candidates. NicOx is applying its proprietary nitric oxide-donating R&D
platform to develop an internal portfolio of New Molecular Entities (NME)
for the potential treatment of inflammatory, cardio-metabolic and
ophthalmological diseases.

NicOx’s lead investigational compound is naproxcinod, an NME and a first-
in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-
inflammatory drug candidate developed for the relief of the signs and
symptoms of osteoarthritis (OA). In July 2010, the FDA provided a Complete
Response Letter to the New Drug Application (NDA) for naproxcinod stating
that it does not approve the naproxcinod application. The naproxcinod
Marketing Authorization Application (MAA) submitted by NicOx in December
2009 is currently under review by the European Medicines Agency (EMA).

In addition to naproxcinod, NicOx’s pipeline includes several nitric oxide-
donating NMEs, which are in development internally and with partners,
including Merck & Co., Inc. and Bausch + Lomb, for the treatment of
hypertension, cardiometabolic diseases, eye diseases and dermatological
diseases.

NicOx S.A. is headquartered in France and is listed on Euronext Paris
(Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although
the Company believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially from
those anticipated in the forward-looking statements. For a discussion of
risks and uncertainties which could cause actual results, financial
condition, performance or achievements of NicOx S.A. to differ from those
contained in the forward-looking statements, please refer to the Risk
Factors (“Facteurs de Risque”) section of the Document de Reference filed
with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on NicOx S.A.’s website
(http://www.nicox.com).

CONTACTS

www.nicox.com

NicOx

Gavin Spencer – Vice President Business Development Tel +33 (0)4 97 24 53
00 – [email protected]

Media Relations Financial Dynamics

Europe

Guillaume Granier (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Stéphanie Bia (France) – Tel: +33 (0)1 47 03 68 10 –
[email protected]

Jonathan Birt (UK) – Tel +44 (0)20 7269 7205 – [email protected]

United States

Robert Stanislaro – Tel +1 212 850 5657 – [email protected]

Irma Gomez-Dib – Tel +1 212 850 5761 – [email protected]

NicOx S.A.,

Les Taissounières – Bât HB4 – 1681 route des Dolines – BP313,
06906 Sophia Antipolis cedex, France. Tel. +33 (0)4 97 24 53 00 – Fax +33
(0)4 97 24 53 99

This information is provided by HUGIN

MERIDIAN, ID–(Marketwire – July 21, 2010) –  MWI Veterinary Supply, Inc. (NASDAQ: MWIV) announced today that the Company will release financial results for its fiscal year 2010 third quarter ended June 30, 2010 and update its business outlook for its fiscal year ending September 30, 2010 on Thursday, July 29, 2010. MWI will host a conference call the same day at 11:00 am eastern time to discuss these results and its business outlook.

For calls within the United States you can access the conference call by dialing (877) 638-4561 and international callers can access the conference by dialing (720) 545-0002. Participants will be required to register their name and company affiliation for the conference call. The conference call will also be carried live on the Company’s website at www.mwivet.com. Audio replay will be made available through August 12, 2010 by calling (800) 642-1687 for calls within the United States or (706) 645-9291 for international calls using the passcode 89688546 or by accessing the Company’s website.

About MWI Veterinary Supply, Inc.:
MWI Veterinary Supply, Inc. is a leading distributor of animal health products to veterinarians across the United States and United Kingdom. The products MWI sells include pharmaceuticals, vaccines, parasiticides, diagnostics, capital equipment, supplies, veterinary pet food and nutritional products. The Company markets these products to veterinarians in both the companion animal and production animal markets.

KANSAS CITY, MO–(Marketwire – July 21, 2010) –  The Translational Medicine Alliance Forum will convene October 13-14, 2010 at the Mandarin Oriental in Washington, DC. This year’s Forum will be hosted by three organizations with the common interest of accelerating translational research to the patient.

The Forum brings together leaders from academia, government agencies, and pharmaceutical, biotechnology and venture industries to work toward developing a deeper understanding of effective models to enable and accelerate the progress of translational medicine. Through focused, dynamic sessions and exclusive networking opportunities, attendees have the opportunity to learn about breakthrough approaches and progress on current best practices in translational medicine collaborations.

“Translational medicine holds some of the most promising advancements, and through this Forum, we are able to help facilitate and encourage a steady pathway to success for current and future research,” said Lesa Mitchell, vice president of Advancing Innovation, Ewing Marion Kauffman Foundation. The Kauffman Foundation helped found the Translational Medicine Alliance in 2007.

This Forum will focus on the following topics: regulatory science, lessons from the most experienced translational models, how and why rare disease and pediatric medicine are changing the landscape, transparency and access to data and reverse engineering translational science starting with the patient. 

The 2010 Forum is cosponsored by the Ewing Marion Kauffman Foundation, FasterCures and the Council for American Innovation. Registration for the Forum is now open. Early bird rates are available now through August 16, 2010, with a rate of $595 for corporate and $200 for academic and not-for-profit registrations. Space is limited. To register for the Forum, visit https://www.regonline.com/2010_translational_medicine_alliance_forum or call 866-831-3243.

Translational Medicine Alliance

The TransMed Partnership was formed in March 2007 to tap into the best ideas of thought leaders and develop an integrated strategy to support and advance the most promising technologies. The Alliance was founded by the Kauffman Foundation, Pfizer, Johnson and Johnson, Biogen Idec, FasterCures, Washington University, St. Louis (WUSTL) School of Medicine, BioVentures for Global Health, the Center for Emerging Technologies, BIOCOM, BIOTECanada, and LifeTech Innovations. For more information about the Alliance, please visit www.translationalmedicinealliance.org.

MUNDELEIN, IL–(Marketwire – July 21, 2010) –  A new VHA case study whitepaper released by Medline Industries, Inc. details how the company used observational studies and context-based design to build human factors and social behaviors into its redesigned Foley Catheter Management tray.

The whitepaper, Social Practice and Clinicians’ Meaning of Urinary Catheter Insertions, showed that the redesigned tray significantly influenced the clinician’s ability to provide high quality care by creating a greater focus on providing patient comfort, maintaining sterile technique and decreasing the time of the entire insertion process. The observational study was comprised of three separate three-day observations of clinicians conducting catheterizations in the emergency department, medical/surgical floors and operating rooms at Providence Sacred Heart Medical Center and Children’s Hospital, Spokane, WA.

“Health care manufacturers are often overlooked when clinicians redesign clinical practices. Yet, the design of a product can be key to helping clinicians improve clinical performance and patient education,” said Trent Haywood, MD, JD, Senior Vice President of Clinical Performance and Chief Medical Officer for VHA and lead investigator. “For example, Medline chose to redesign the urinary catheter tray based upon the observational data uncovered in the clinical setting. Such design emphasis shows how manufacturers can be a key partner in quality and safety.” 

The unique partnership between Medline and the VHA research team highlights how industry vendors can partner with healthcare providers to develop a comprehensive system that incorporates proper procedures and social behaviors that are easy to adopt in every day practice.

Medline launched its ERASE CAUTI program, which is based on the same criteria the CDC used in developing their new CAUTI prevention guidelines, last fall. Soon after the tray’s introduction, Medline met with the VHA Clinical Performance team to discuss studying the tray and how it’s used in actual clinical practice. Emphasis was put on understanding the objectives of catheter insertions from the clinician’s perspective, clarifying the actual practice that unfolds and identifying areas where the catheter management system aided the clinician or failed to aid the clinician based upon the clinician’s perspective on the practice.

Findings summarized in a case study whitepaper showed that clinicians preferred the benefits of the single layer tray which did not require steps related to maneuvering and positioning with a two layer tray. They also preferred the change to swab sticks that decreased the number of steps in the prepping and cleansing of the perineum. Clinicians retained the patent-pending patient education card for the patient or placed it in location where the patient might review it — a departure from previously observed behavior where the education was discarded without much attention. Clinicians also used the full-colored photography packaging to better explain the procedure to patients.

“Chief Nursing Officers (CNOs) want to help their staff reduce variability in the procedures that are done so that the potential to make an error decreases,” said Connie Yuska, Medline’s Vice President of Clinical Services and a former CNO. “We redesigned the tray taking into account the interaction between the patient and the clinician and facilitate learning — things that challenge nursing leaders every day.”

The VHA whitepaper, as well as additional information on the ERASE CAUTI program, is available for download on Medline’s website at www.medline.com/erase.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

MUNDELEIN, IL–(Marketwire – July 21, 2010) –  Medline Industries Inc., the nation’s largest privately held manufacturer and distributor of healthcare supplies, announced today the signing of a cost management prime vendor agreement with the AROK Purchasing Coalition, a VHA supply network comprised of nearly 50 acute care facilities in Arkansas and Oklahoma. The five-year agreement is anticipated to save AROK an estimated $20-$25 million over the term of the contract.

Medline is expected to generate more than $500 million in medical and surgical product sales from the partnership over the term of the agreement. 

AROK was formed to help VHA member hospitals in Arkansas and Oklahoma increase efficiencies and reduce expenses by aggregating supply and services expenditures. 

As part of the agreement, Medline will provide its broad array of Medline brand medical and surgical products, including surgical procedure trays, patient care products, disposable protective gowns, exam gloves and bandages. Medline will drive cost savings to AROK members by delivering products direct to the healthcare facilities from two of Medline’s distribution centers located in Oklahoma City and Memphis, Tenn.

Medline will also deliver cost savings by reducing distribution fees on other national brand products and product standardization. In addition, Medline will provide enhanced reporting capabilities and offer comprehensive product utilization, education and practical solutions to help the facility control costs and improve patient care. 

About AROK
The AROK Purchasing Coalition is a VHA Supply Network. Twenty-one VHA health care organizations, representing nearly 50 hospitals in Arkansas and Oklahoma officially joined together in June 2008 to increase efficiencies and reduce expenses by aggregating supply and services expenditures. Combined annual supply purchases of the purchasing coalition represent in excess of $600 million. As a limited liability corporation, the AROK Purchasing Coalition is recognized as a single VHA member entity and as a large integrated delivery system by the supplier and distributor community. VHA operates the purchasing coalition at the direction of the members.

About Medline Industries, Inc. 
Medline, the nation’s largest privately held manufacturer and distributor of healthcare products, manufactures and distributes more than 100,000 products to hospitals, extended-care facilities, surgery centers, home care dealers and agencies. Headquartered in Mundelein, Ill., Medline has more than 900 dedicated sales representatives nationwide to support its broad product line and cost management services.

Over the past five years, Medline has been the fastest-growing distributor of medical and surgical supplies in the U.S., serving as the primary distributor to over 450 major hospitals and healthcare systems. As a leading distributor, Medline offers a comprehensive array of consulting and management services encompassing the supply chain and logistics, utilization and standardization, business tools and enhanced reporting capabilities and on-staff clinicians.

Medline has a growing network of 32 distribution centers around the country, as well as an expanding, dedicated transportation fleet with over 200 vehicles in a variety of sizes to fit customers’ specific delivery needs. The fleet is equipped with the latest navigation devices for enhanced order tracking and communication.

About VHA
VHA Inc., based in Irving, Texas, is a national network of not-for-profit health care organizations that work together to drive maximum savings in the supply chain arena, set new levels of clinical performance and identify and implement best practices to improve operational efficiency and clinical outcomes. Formed in 1977, through its 16 regional offices, VHA serves more than 1,400 hospitals and more than 25,500+ non-acute care providers nationwide. VHA was ranked by Modern Healthcare as the 7th best place to work in health care in 2009.

PRINCETON, NJ–(Marketwire – July 21, 2010) – In a recent USA Today article, medical tourism is getting a huge boost from American based employers and insurers who encourage employees to consider domestic medical travel. Therefore, instead of seeking out medical travel or affordable healthcare alternatives overseas such as Thailand or India, employees are being directed to regional facilities that offer high-quality care and lower prices. “The move is reducing healthcare costs by 20% to 40%, with the difference often covering travel expenses,” says David Goldstein, President of Health Options Worldwide (HOW), an online medical tourism company.

“When people hear the words ‘medical tourism,’ they automatically think overseas,” explained Goldstein, “But low-cost healthcare can be found in this country, even if it involves some travel.” Employers who offer domestic medical travel programs can save healthcare money by negotiating a single rate. This rate can include surgical and anesthesia fees and all medical care performed up until discharge.

Large corporations like Lowe’s, the home improvement retailer, already have such programs in place. A self-insured employer, Lowe’s struck a deal with a cardio care clinic where they send their employees for open-heart surgeries, valve repairs and pacemakers. In the future, they may add orthopedic surgeries to their program. Other large employers may soon follow suit with similar agreements with healthcare providers. Some companies provide financial incentives to medical travelers like waived deductions, copayment reductions and paid travel expenses.

“If this concept catches on, especially with large employers, it could help decrease healthcare costs and improve the quality of medical care by creating a competitive marketplace,” says Goldstein. Hospitals dictate costs and affect health insurance premiums. “However, it’s very sobering to see how much medical costs and quality can vary between hospitals and regions,” said Goldstein.

However, the focus should still be on quality along with financial balance, advises Goldstein. “With tempting financial incentives, employees may be forced to choose cost instead of quality, and the choice will be taken out of their hands,” explained Goldstein. Still the savings are hard to beat, especially when there are fewer complications from procedures that are done with high quality providers. Follow-up care, like physical therapy, is done locally and covered under the employee’s regular insurance plan.

Programs like these could spur the domestic healthcare marketplace to respond with even lower costs in order to lure patients to their centers. Insurance companies are hesitant to offer domestic medical travel incentives because it creates ill will with local healthcare providers, who then lower their costs in response. “This is why employers, healthcare providers and insurance companies will have no choice but to embrace this trend,” said Goldstein.

Click here to see all recent news from this company

ROCKVILLE, MD and SEOUL, KOREA–(Marketwire – July 21, 2010) – The emergence and spread of drug-resistant mycobacterium tuberculosis (TB) threatens global TB control efforts, and there is an urgent need for new diagnostic tests that rapidly identify drug sensitivity profiles of TB strains. To help address these concerns, Seegene today introduced Anyplex™ MDR-TB Screening Test, the first real-time PCR molecular diagnostic capable of simultaneous detection of TB and genetic mutations leading to multi-drug resistant TB (MDR-TB) within four hours.

Seegene Anyplex™ MDR-TB Test will be introduced at the 2010 Annual Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), booth #1800.

According to the World Health Organization (WHO), TB strains that are resistant to all major anti-TB drugs have been documented in every country by the non-governmental organization recent survey. A particularly dangerous form of drug-resistant TB is multi-drug resistant TB (MDR-TB), which is defined as the disease caused by TB bacilli resistant to, among others, the two most powerful anti-TB drugs, isoniazid (INH) and rifampicin (Rif).The rate for successful MDR-TB treatment is extremely low and the progress of the disease is faster than normal TB, resulting in 40-50% of mortality rate. Rates of MDR-TB are troublingly high in some countries, especially in the former Soviet Union, and threaten TB infectious disease control efforts. WHO estimates that more than 440,000 people are infected with MDR-TB.

Using Anyplex^™ MDR-TB Screening Test, healthcare workers will be able to quickly determine whether or not a patient is infected with a strain of TB that is resistant to INH and Rif. The Anyplex^™ MDR-TB is a real-time detection test of M. tuberculosis that quickly and comprehensively determines the levels of targets in a patient’s various sample types, and identifies mutations of drug resistant genes to better inform a diagnosis.

Because genetic mutations that lead to antibiotic resistance are minute and sit close together, so far conventional PCR or conventional real-time PCR tests are not able to discriminate these mutations accurately within the same test procedure. In contrast, the Anyplex MDR-TB test can detect the mutations of drug resistant genes to Rif (rpoB: D516V/Y, H526D/Y, S531L) and INH (katG: S315T (2 cases); inhA promoter: -15(C/T)). The unprecedented speed and accuracy of the Anyplex MDR-TB Tests will enable doctors and clinicians to quickly provide an appropriate treatment to prevent the spread of MDR-TB.

Seegene’s new MDR-TB test takes TB diagnostics to a new level. Current TB test methods are hindered by speed (culture typically required 2-8 weeks for results), low sensitivity (acid-fast bacilli smear microscopy produced results in 24 hours but at the cost of missing a significant portion of TB cases) and low specificity (culture and microscopy methods not being able to efficiently differentiate between M. tuberculosis and non-tuberculosis mycobacteria). Furthermore, none of these approaches are able to rapidly and efficiently identify a patient’s resistance to the major drugs for treating TB — INH and Rif. Even if sequencing and Line Probe Assay are available to test drug resistance, the procedures are quite complicated and time-consuming.

“Making a fast and accurate diagnosis of the type of TB infection a patient may have is the most important step to curing a patient. Because MDR-TB is difficult to treat, preventing its spread throughout the population is essential. The Anyplex^™ MDR-TB Test is a powerful new tool that healthcare workers can use to rapidly determine MDR-TB infections, which will both help stop it from spreading and allow health care professionals to set a course of alternative medications for infected patients,” said Jong-Yoon Chun, chief executive officer of Seegene.

Anyplex^™ MDR-TB Test will not be available in the USA until regulatory clearance.

About Seegene

Seegene, Inc. is the leading biotechnology company developing, manufacturing and marketing innovative molecular diagnostic products. The company’s proprietary technologies in both PCR and Real-time PCR named ACP™, DPO™, and READ™, set a new solution for high-throughput and simultaneous multi-pathogen detection called “multiplex PCR”. The novel Real-time PCR technology, READ™, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex^®  system adapting DPO™ Technology, Anyplex™ and Magicplex™ systems that are Real-time PCR detection platforms adapting DPO™ and READ™ technologies. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using the innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.